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POPULAR SCIENCE SUMMARY OF THE THESIS 
During pregnancy, diseases and conditions can affect the health of the woman and foetus. My interest, 
and what we have studied, is how rheumatic conditions affect pregnancies. One rheumatic condition is 
arthritis, which is characterised by inflammation of the joints. Arthritis is a rare condition, so it can be 
an advantage to study this via national registers instead of in real life. Otherwise, it would take too 
long to gather enough information to draw conclusions. In this thesis, two arthritis conditions were 
studied: juvenile idiopathic arthritis (JIA), which is the most common childhood rheumatic disease, 
and psoriatic arthritis (PsA). We collected information on these conditions from population-based, 
nationwide Swedish registers and from a rheumatology quality register which contains more detailed 
clinical information about patients’ disease. The personal identity number enables linkage between 
these registers. Data is anonymised and an ethical permit is needed. 
In study I, we examined if there were more complications in pregnancies and births where the woman 
had a diagnosis of JIA before pregnancy, compared to pregnancies in women without such diagnosis. 
There were increased risks of complications in JIA pregnancies, including preterm birth (birth before 
37 weeks of pregnancy), a baby born small for its age, pre-eclampsia (a hypertensive disease confined 
to pregnancy) and caesarean delivery. 
In study II, we studied if pregnancies in women with PsA had increased risks of complications 
compared to pregnancies in women without PsA. In this study, we also used registers to identify 
pregnancies with PsA and variables that describe pregnancy outcomes. Compared to non-PsA 
pregnancies, PsA pregnancies had increased risks of preterm delivery and caesarean delivery. These 
associations were influenced by whether it was the first or subsequent pregnancy in a woman, with 
first pregnancies having the highest risks. 
In study III, we continued to study PsA pregnancies compared to non-PsA pregnancies, and we 
wanted to find out if a more severe PsA disease was more prone to complications than a mild disease. 
We used treatment with different antirheumatic drugs as a proxy for PsA disease severity. We 
considered pregnancies with no treatment as mild and those with multiple drugs or treatment 
throughout pregnancy as more severe. In this study, we concluded that pregnancy outcomes differed 
with disease severity, with the most increased risk for pre-eclampsia and preterm birth seen in 
pregnancies with antirheumatic treatment during pregnancy compared to non-PsA pregnancies. 
In study IV, we wanted to investigate if disease activity influenced the risk of giving birth preterm. 
There are standardised ways to assess disease activity by a composite of clinical evaluation and 
biochemical testing. This assessment results in a score which can be used to evaluate disease activity 
in the clinical setting together with other factors. In a research setting like our study, the score alone 
can be used to characterise disease activity. All pregnancies in this study had PsA. We divided them 
into two groups based on whether they had any disease activity score indicating moderate or high 
active PsA disease or not. We assessed disease activity in the time period from one year before start of 
pregnancy until delivery. In pregnancies with a disease activity score indicating moderate or high 
active PsA disease any time during the study period, 13% had a preterm birth compared to 7.8% of 
those with scores indicating low active PsA disease. In conclusion, we found a numerical but not 
statistically significant difference between the proportions of preterm birth among PsA pregnancies 
with vs. without active disease during pregnancy. 
 
To conclude: the studies included in this thesis indicate that pregnancies with JIA or PsA have less 
favourable outcomes compared to pregnancies without arthritis disease. However, most PsA and JIA 
pregnancies are also uneventful. The risk of preterm birth is influenced by disease severity and by 




The aim of this thesis was to add to the existing knowledge of how inflammatory arthritis disease 
affects pregnancy outcomes. In particular, the aim was to describe and study the effects of a diagnosis 
of juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) on pregnancy outcomes, to further 
study the effect of disease severity in PsA on pregnancy outcomes and lastly to study the association 
of disease activity and preterm birth in pregnancies with PsA. To address these aims we used 
information from Swedish population based registers such as the Medical Birth Register (MBR), the 
National Patient Register (NPR), the Prescribed Drug Register (PDR) and the nationwide clinical 
quality register, Swedish Rheumatology quality register (SRQ). 
In study I-III, we used regression models to estimate odds ratios (ORs) with 95% confidence intervals. 
In study I, we assessed pregnancy outcomes in a nationwide population based cohort of singleton 
pregnancies between 1992 and 2011. We identified 1807 pregnancies to women with a diagnosis of 
JIA and 1 949 202 comparator pregnancies to women without JIA. Due to the fact that JIA is a 
heterogenic condition, which may or may not persist into adulthood, we stratified the pregnancies with 
JIA into two groups: JIA paediatric only (n=1169), where the diagnosis was confined to childhood 
and/or adolescence, and JIA persisting into adulthood (n=638). In conclusion, we observed increased 
risks of preterm birth and caesarean delivery for both JIA groups compared to comparator 
pregnancies. In addition, we observed increased risks of pre-eclampsia and small for gestational age 
(SGA) birth in pregnancies with JIA persisting into adulthood. 
In study II, we studied pregnancy outcomes in a cohort of 41 485 singleton pregnancies from 1997 to 
2014 assembled by linkage of national registers. We identified 541 first and subsequent singleton 
pregnancies with PsA exposure and 40 944 pregnancies were identified as unexposed during the same 
time period. Pregnancies to women with PsA had increased risks (estimated with aORs) of preterm 
birth and caesarean delivery compared to unexposed pregnancies. 
In study III, the focus was to assess how disease severity of PsA (by use of a proxy, i.e. antirheumatic 
treatment) affected pregnancy outcomes in comparison with non-PsA pregnancies. We defined the 
study period from 2007 to 2017 to be able to use information from the prescribed drug register. The 
main study cohort consisted of 921 PsA pregnancies and 9210 matched (on parity, maternal age and 
year of birth) non-PsA pregnancies. In the main analysis there were increased risks of preterm birth 
and caesarean delivery in PsA as compared to non-PSA pregnancies. We thereafter stratified the 
cohort of PsA pregnancies based on presence, timing and type of antirheumatic treatment. The risks of 
preterm birth and caesarean delivery differed among these groups, with the most increased risks 
among PsA pregnancies (vs. non-PsA) with antirheumatic treatment during pregnancy. Risk of 
preterm birth was influenced by parity and mainly increased in first pregnancies. 
In study IV, we used information from SRQ and MBR to assemble a cohort of 211 pregnancies from 
2007 to 2017. All identified pregnancies had a diagnosis of PsA assigned by the treating 
rheumatologist. We aimed to assess the association of disease activity, in the time period from one 
year before pregnancy until delivery, and preterm birth. Disease activity was assessed with registered 
values of DAS28CRP and values of health assessment questionnaire (HAQ). We dichotomised the 
exposure into moderate/high disease activity and low disease activity. The proportion of preterm birth 
was higher in pregnancies with any registered moderate/high disease activity in the year before and/or 
during pregnancy (vs. not). We found a numerical but not statistically significant difference between 
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1.1 BACKGROUND AND CLINICAL CONTEXT 
As an obstetrician, I meet and care for women having different types of medical conditions 
during their pregnancy and labour. In the beginning of my clinical career as an obstetrician in 
the late 1990s, I met many pregnant women with inflammatory rheumatoid conditions, most 
frequently severe systemic lupus erythematosus (SLE). I was taught that oestrogen and 
pregnancy may worsen some inflammatory conditions – such as SLE – whereas it could, 
conversely, induce amelioration for those with rheumatoid arthritis (RA). I remember that the 
women with RA were quite affected by their disease, not seldom in wheelchair and very often 
with visible destruction of joints. We often admitted them to in-patient care because of 
deterioration of symptoms or a need of surveillance. A few years after the new millennium, 
the patient panorama was totally different. Presumably, this was due to changes in the 
available treatment options, such as the introduction of biological disease-modifying anti 
rheumatic drugs (bDMARDs) including tumour necrosis factor inhibitors (TNFi). 
These changes in the patient panorama, which we saw within the specialised obstetric care, 
sparked my curiosity about this group of pregnant women and this area of research. 
With respect to pregnancy outcomes, RA is the most studied of the chronic inflammatory 
arthritis diseases. Due to a lack of specific information for other inflammatory arthritis 
diseases, results from studies on RA during pregnancy are often generalised to these 
conditions as well. In the clinical setting, disease specific information is needed to plan 
surveillance and care during pregnancy, as well as to inform and discuss expectations with 
the woman. Probably, some aspects of RA and pregnancy are indeed generalisable, but there 
may be differences that could be important to address. 
Treatment options for various inflammatory conditions have increased and improved during 
recent years, why there is a need both to assess pregnancy outcomes in a contemporary 
patient population with adequate anti-rheumatic treatment and to further elucidate and 




2 LITERATURE REVIEW 
2.1 INFLAMMATION AND PREGNANCY 
Chronic inflammation, such as RA and inflammatory bowel disease (IBD), has been 
associated with an increased risk for adverse pregnancy outcomes (1-7) presumably linked to 
effects of inflammation, presence of autoantibodies, co-morbidities and medical treatment 
(7). Immunological, epidemiological and clinical evidence suggest that female sex hormones 
play an important role in the aetiology and pathophysiology of chronic immune and 
inflammatory diseases (7-9). 
Outside pregnancy, the immune system is designed to protect the body from non-self-
antigens, whereas self-antigens are expected to be tolerated. However, if a reaction against 
self-antigens occurs, it is generally considered to be an autoimmune reaction. Pregnancy is an 
exception, which induces changes in the immune system to tolerate the foetus, i.e. the 
immune system tolerates non-self tissues. The mechanisms underlying this tolerance have 
been the focus of research, but are not fully understood. 
2.2 INFLAMMATORY ARTHRITIS AND PREGNANCY 
In women with inflammatory arthritis, various adverse pregnancy outcomes have been 
reported for both the mother and the neonate. During pregnancy, pre-eclampsia is described, 
(5, 6, 10, 11) and in terms of mode of delivery, increased frequencies of caesarean deliveries 
are reported in women with inflammatory arthritis disease (10-15). Among foetal/neonatal 
complications, the most frequently described are preterm birth and neonates born small for 
gestational age (SGA) (2, 3, 6, 7, 14). 
In 2016, Wallenius et al. published an informative study on reproductive trends in women 
with inflammatory joint disease (IJD); juvenile idiopathic arthritis (JIA), RA, psoriatic 
arthritis (PsA) and spondylarthritis (SpA), with respect to calendar time (14). The authors 
reminded the reader about the fact that several women with inflammatory arthritis were 
discouraged from pregnancy as late as the 1990s. Since then, the proportion of women with 
inflammatory disease who give birth has gradually increased, while adverse pregnancy 
outcomes have decreased (14). Also, diagnostic criteria have changed during the years, as 
well as available treatment and treatment strategies, both outside pregnancy (treat-to-target) 
and during pregnancy. In fact, TNFi are now accepted in guidelines for use in the first two 
trimesters for those with moderate or severe disease activity (6, 16-18). 
In another study, Wallenius et al. (4) reported on adverse pregnancy outcomes in women with 
inflammatory arthritis related to birth-order, i.e. if the first birth was before or after diagnosis 
of inflammatory arthritis (4). This study describes increased frequency of pregnancy 
complications compared to the general population, but mainly in the first birth after diagnosis 
(14). 
2.2.1 Rheumatoid arthritis 
RA is a chronic inflammatory arthritis characterised by symmetric small joint polyarthritis, 
systemic inflammation and inflammation of the synovial membrane surrounding the joint. 
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The onset is usually at 40-70 years of age, and the disease is 2-3 times more common in 
women than in men. Furthermore, the onset of disease in women is common during times in 
life when sex hormones are fluctuating, such as the postpartum period and around the time of 
menopause (19). The prevalence of RA is approximately 0.5-1% in Western countries and the 
incidence among Swedish women is 56 per 100 000 (20, 21). 
There is no diagnostic test for RA. Thus, the diagnosis is based on classification criteria and a 
physician’s assessment. Since 2010, the updated ACR (American college of 
rheumatology)/EULAR (European league against rheumatism) scoring criteria for 
classification of RA are in use (22) (Table 1). The criteria focus on the early stages of the 
disease and distinguish between two different phenotypes based on serology, where presence 
of anti-citrullinated protein antibodies (ACPA) and/or rheumatoid factor (RF) is used (ACPA 
positive/negative or RF positive/negative). The criteria are intended for use in a target 
population with patients who: a) have at least one joint with definite clinical synovitis 
wherein b) the synovitis is not better explained by another disease. To be classified as RA, an 
overall score of ≥6 according to ACR/EULAR is required. 
Table 1. ACR/EULAR scoring criteria for classification of RA 
A. Joint involvement Score 
1 large joint 
2-10 large joints 
1-3 small joints 
4-10 small joints (with or without involvement of large joints) 






B. Serology (at least 1 test result is needed for classification) Score 
Negative RF and negative ACPA 
Low-positive RF or low-positive ACPA 




C. Acute-phase reactants (at least 1 test result is needed for classification) Score 
Normal C-reactive protein (CRP) and normal erythrocyte sedimentation rate (ESR) 
Abnormal CRP or abnormal ESR 
0 
1 





2.2.1.1 Disease activity and severity 
An activity index is of importance to determine disease activity, but the treating 
rheumatologist has to evaluate also clinical findings and bio-chemical variables to define 
disease activity since there is no single test to assess disease activity or level of inflammation. 
The activity index can be used to support the decision making. 
The most widespread measure of disease activity is the 28-joint disease activity score 
(DAS28), which was originally developed to describe results in clinical trials (23). This index 
is a composite value consisting of swollen (0-28) and tender joint count (0-28), erythrocyte 
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sedimentation rate (ESR) and the patient’s general health assessment on a visual analogue 
scale (0-100). Different versions of DAS28 are available. DAS28CRP (3) is calculated based 
on three variables: swollen and tender joint count and CRP. DAS28CRP (4) includes also 
patient global assessment (24). 
DAS28 < 2.6 is defined as remission, DAS28<3.2 as low disease activity, DAS28 3.2-5.1 as 
moderate disease activity and DAS28>5.1 as high disease activity. When DAS28 is 
calculated based on CRP instead of ESR the same definitions are used (25, 26). 
Health assessment questionnaire (HAQ) is an index of patient rated functional ability where a 
low value indicates good functional ability. With this index the restrictions of daily life 
activities due to the disease can be assessed. Stanford HAQ, full HAQ or HAQ- disability 
index (HAQ-DI) all refers to the original HAQ which was developed for use in patients with 
RA. The modified HAQ (mHAQ) is a shorter version of the full HAQ. 
2.2.1.2 Pregnancy outcomes in RA pregnancies 
RA is the most frequently studied condition among the chronic inflammatory arthritis during 
pregnancy. In 1938, Hench published a classic study about amelioration of RA related 
symptoms during pregnancy, and a similar pattern has been confirmed in later publications 
and by clinical experience throughout the years. (7) In more recent years, the PARA study (1, 
27-31) (pregnancy-induced amelioration of rheumatoid arthritis), consisting of a nationwide 
prospective cohort of about 245 RA women, (32) has contributed important insights on this 
subject in a more contemporary RA population. The percentage of patients who improved 
during pregnancy varied between 39-75%, depending on, among other things serological 
status (6, 33, 34). In one of the studies, the authors conclude that women with seronegative 
disease were more likely to improve during pregnancy as compared to those with seropositive 
disease (30). Increased disease activity postpartum was not dependent on serological status in 
this study population (30). In 2017, Ince-Askan et al. (31) published a study, also embedded 
in the PARA study, which reported that women with RA and a low disease activity score (in 
this study defined as DAS28CRP <3.2) were more likely to have a low disease activity score 
or to reach remission in the third trimester. This was irrespective of autoantibody status or use 
of prednisone (corticosteroid treatment). Also, women with higher disease activity who were 
not taking prednisone and lacked autoantibodies still had, as the authors phrased it, “a fair 
chance of low disease activity in the last trimester”. The opposite was noted for those with 
positive autoantibody status and a moderate or severe disease activity (DAS28CRP ≥3.2) in 
the first trimester; only 5.5% of these women were in remission in the third trimester (31). 
Notably, none of these women used bDMARDs and no other obstetrical outcomes regarding 
the mother and infant were studied. 
Overall, studies have shown that neonates born to women with RA are more frequently born 
SGA and preterm, that this can to some extent be associated with disease activity (5, 6, 27), 
whereas the effect of corticosteroids on birth weight seems to be mediated by shorter 
gestational length at time of birth (27). Norgaard et al. observed an effect of autoantibody 
status when assessing pregnancy outcomes in a large Danish-Swedish population based 
cohort, comparing first time singleton pregnancies in mothers with RA to general population 
comparators (5). The adjusted odds ratio (aOR) for preterm birth, both moderately and very 
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preterm, were increased in the RF-positive group 1.65 (95%CI 1.23-2.23) and 2.04 (95%CI 
1.18-3.53), respectively. No statistically significant associations were seen in the RF-negative 
group. The same pattern was seen when analysing the outcome of SGA births. There was also 
an increased prevalence of pre-eclampsia and caesarean deliveries when comparing women 
with RA to general population controls (5, 11). 
The effect of corticosteroids on adverse outcomes is discussed in a systematic review by 
Bandoli et al. (35). The authors summarise that the use of corticosteroids during pregnancy 
may be associated with a modest increase of cleft lip (congenital malformation), but data are 
conflicting. Further, it is unknown to what extent maternal disease also affects this outcome. 
Bandoli et al. also state, with regard to systemic corticosteroid use during pregnancy, that 
there is little evidence of an independent risk increase of corticosteroids on preterm birth, low 
birth weight or pre-eclampsia. 
Bharti et al. have performed a prospective cohort study of 440 women with RA to determine 
the effect of RA disease severity on pregnancy outcomes. Data collection period was from 
2005-2013. This was a study on subjects enrolled in an ongoing project, inclusion criteria 
were birth of a live born singleton infant and that the subjects completed three telephone 
based measures of RA disease severity, prior to 20 weeks of gestation and after two and four 
weeks postpartum respectively. The measurements of RA disease severity included the health 
assessment questionnaire disability index (HAQ-DI), pain score and patients global scale. 
Data was self-reported and verified with medical records. The outcomes studied were preterm 
birth, SGA birth and caesarean delivery. The authors report an association between HAQ-DI, 
when used as a continuous variable and measured in early pregnancy, and preterm birth. No 
association was found for HAQ-DI and caesarean delivery. Overall, the women in the study 
population had a low median HAQ-DI of 0.25 indication mild disease (36). 
In 2019, Kishore et al. reported from a cross-sectional study where they compared pregnancy 
related admissions for women with RA and without where they used data from a nationwide 
inpatient database in the United States of America 2003-2011 (37). They identified 31 439 
women with RA and 42 286 209 comparators without RA in the database. There were 
increased aOR of hypertensive diseases, premature rupture of membranes, antepartum 
haemorrhage, preterm birth, intrauterine growth restriction and caesarean delivery. The 
analyses were adjusted for age and co-morbidities. They did not have data on disease activity 
or antirheumatic treatment. This study is included in this literature review because it is a 
contemporary US based study with possibly a more diverse study population than in the 
smaller studies from Organization of Teratology Information Specialists (OTIS) Autoimmune 
Diseases in pregnancy Project (38, 39) which are described in the next paragraph about JIA. 
2.2.2 Juvenile idiopathic arthritis 
Juvenile idiopathic arthritis (JIA) encompasses a heterogeneous group of clinical phenotypes 
characterised by onset of arthritis before the age of 16 years. JIA constitutes the most 
common childhood rheumatic condition (40). JIA can mainly be divided into five subgroups 
depending on symptoms, number of joints affected by inflammation and serological markers 
(Figure 1). Since 1997, the International league of associations for rheumatology (ILAR) 
criteria are used for classification and an internationally accepted nomenclature for the 
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condition (JIA) is established. The incidence is estimated to 15/100 000 children and year in 
Sweden and to 11-14/100 000 children and year in the Nordic countries (41). 
Figure 1. Subgroups of JIA according to the 1997 ILAR criteria. 
 
 
Although the natural course of JIA is variable and may include remission, more than one 
third of all JIA patients have persisting disease into adulthood (42, 43). JIA may impact 
health in adulthood through several mechanisms: ongoing inflammatory activity and 
exposure to immune-modulatory therapies, systemic effects of past inflammatory activity 
such as impaired growth during adolescence and local effects such as joint destruction (44). 
2.2.2.1 Pregnancy outcomes in JIA pregnancies 
With respect to pregnancy outcomes in patients diagnosed with JIA, Ostensen et al. reported 
in 1991 on 76 pregnancies in women with JIA and suggested an increased risk of caesarean 
delivery (45). In 2013, Chen et al. reported on 78 births in women with JIA and found 
increased risks of caesarean delivery, pre-eclampsia and preterm birth (13). Ehrmann 
Feldman et al. reported 2016 on a large Canadian cohort study of first births to women with a 
history of JIA (n=1681). The study focused on neonatal outcomes and reported on higher 
proportions of prematurity, SGA and congenital malformations in the infants to women with 
a history of JIA as compared to infants born to mothers without JIA (46). The same authors 
published a study in 2017, using presumably the same study cohort, focusing on maternal 
postpartum outcomes. They describe an increased risk of venous thromboembolism (VTE) in 
mothers with JIA compared to unexposed mothers. The low number of events did not allow 
for full adjustment of covariates, but after adjustment for caesarean delivery the odds for 
VTE were increased 5-fold OR 5.29; 95% CI 1.84 -15.21. Similar results were found when 
adjustments for maternal age and pre-eclampsia, respectively, were performed in separate 
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analyses. The authors concluded: “Mothers with JIA appear to be at higher risk for 
complications from anaesthesia, postpartum haemorrhage and thromboembolism” (46). 
Mohamed et al. studied the risk of preterm birth and restricted foetal growth in pregnant 
women with diagnosis of juvenile rheumatoid arthritis (JRA) compared to pregnant women 
without this diagnosis (47). It was a US based cross sectional study comprising women who 
delivered between 2011 and 2012. 1236 women had a diagnosis of JRA. Overall, the 
authors found an increased risk of preterm birth aOR 2.1, 95% CI 1.74- 2.42 in women with 
JRA compared to non-JRA. When stratified by race there were differences, aOR for 
preterm birth in Hispanic JRA women was 4.43 95% CI 2.97-6.62 compared to non-JRA 
Hispanic women and aOR for preterm birth in white women with JRA compared to non-
JRA was 1.78, 95% CI 1.41-2.24. The proportion or odds of having a SGA birth did not 
differ between JRA and non-JRA women. Asians and Pacific Islanders did not have 
increased odds of preterm birth. The authors’ state that they have defined the outcome 
preterm birth with ICD 9 code 644.0, with a reference to a webpage and year of access 
2015. To my understanding this code refers to threatening premature labour (644.2 
corresponds to early onset of delivery). Thus, the results from this study have to be 
interpreted with caution. 
Ursin et.al. studied disease activity of JIA in 114 women (135 pregnancies) during and after 
pregnancy (48). Disease activity was assessed with DAS28CRP3 at seven time points 
before, during and after pregnancy when also self-reported physical function, pain and 
mental health was assessed. The study was register based and included pregnancies from 
2006-2015. Women with at least one registered measurement from the first trimester to one 
year after delivery were included. The EULAR criteria was used to define categories of 
disease activity as in remission, low disease activity, moderate disease activity and high 
disease activity. Self-reported medical outcomes study short form (SF-36), a modified HAQ 
and information on medication were collected at each visit. The proportion of women using 
a DMARD (in this study synthetic, biological or both) decreased from 55% before 
pregnancy to 22% in pregnancy. 48 women discontinued bDMARD in the year prior to 
pregnancy. Of these, 23 did so more than three months before, 17 less than three months 
before and 8 at the time of confirmed pregnancy. Less than 5% of the women used 
bDMARD during pregnancy. 
Almost 80% of the women in the study were in remission or had low disease activity 
throughout the study period. The authors conclude that disease activity was stable but was 
increased at the assessment six weeks postpartum. The patient reported MHAQ were 
highest in the third trimester corresponding to the lowest functionality. This was in line 
with the result from the physical functioning score of SF-26 which also was lowered in the 
third trimester compared to six weeks postpartum. 
Apart from the study on exclusively women with RA mentioned in the previous RA-
paragraph (36) a more recent study was published in 2019 on data from the same ongoing 
project: OTIS Autoimmune Disease in Pregnancy Project where pregnant women with both 
RA and JIA as well as comparison women were assessed regarding effects of maternal 
disease activity, medication use and pregnancy conditions effect on risk for preterm birth 
(39). 170 women with JIA, 657 women with RA and 564 comparison women without 
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autoimmune diseases were included. Live born infants from 2004 to 2017 were included in 
the analysis. Disease activity was documented at intake and at 32 weeks of gestation using 
patient reported assessments HAQ, pain score and patient global disease activity 
assessment which were used to calculate the patient activity scale (PAS) score where high 
disease activity was defined as PAS score >3.7 and low disease activity as ≤3.7. Active 
disease was associated with preterm birth in women with RA but not in JIA. After 
adjustment (including for disease activity) corticosteroid use in any trimester was 
significantly associated with preterm delivery in both women with RA and JIA. Neither 
DMARDs nor biologics were associated with increased risk for preterm birth. Further, pre-
eclampsia, pregnancy induced hypertension and gestational diabetes were independently 
associated with a higher risk for preterm birth among women with RA but not in women 
with JIA. In women with JIA fever and NSAID medication were associated with preterm 
birth. The authors discuss if this may be indicators of active disease not captured by the 
disease activity measures used in the study. 
In 2019 Förger et al. published another study from the OTIS Autoimmune Disease in 
Pregnancy Project with the aim to study patterns of TNFi continuation or discontinuation 
during pregnancy in association with changes in disease activity during pregnancy (38). 93 
women with JIA were included together with 397 women with RA. Unfortunately, JIA was 
not analysed separately. In the study, 323 women (65.9%) received a TNFi during 
pregnancy and 122 discontinued before gestational week 20. 201 women continued their 
treatment and 116 of these women continued until term gestation. 85 women discontinued 
at a mean gestational age of 32 weeks. 167 women in the study did not receive any TNFi 
during pregnancy. At inclusion in the study, disease activity was low to minimal measured 
with PAS scores ≤3.7. In conclusion, the authors did not find a risk of worsening disease 
activity after discontinuation of TNFi before gestational week 20. 
In 2020, a register based study from Taiwan was published including first singleton births 
in women with two diagnosis of JIA (defined by the authors) before 16 years of age and 
five matched, on maternal age and birth year, births to women without JIA (49). For infant 
outcomes the authors report increased aOR for low birth weight but comment that the 
absolute difference compared to the reference population was small. No difference with 
respect to outcomes preterm birth or SGA birth were seen. Regarding maternal outcomes 
there were no statistically significant differences. The authors discuss that sub types of JIA 
can differ between a Caucasian population, where pauciarticular arthritis is the most 
common subtype and an Asian population where enthesitis related arthritis is more 
common and that this may be a factor that contributes to the favourable outcomes seen in 
this study. 
Recently, a study from Germany with data from two ongoing multicentre prospective 
observational cohorts the JIA registry Biologics in Paediatric Rheumatology (BiKeR) and 
its follow up register Juvenile arthritis Methotrexate/Biologics long term Observation 
(JuMBO) was published (50). They investigated the course and outcome of pregnancy in 
women with diagnosis of JIA (or recruited as female partners to a male JIA patient) and 
with long term or until pregnancy use of DMARDs during 2007-2018. 
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Patients were assessed every 6 months and both rheumatologist and patient reported 
outcomes were collected. Information about pregnancy was gathered once early in 
pregnancy and when the infant was 6 months of age. If complications were reported, 
written medical reports were requested from the attending physicians. The outcomes 
studied were disease activity measured with clinical arthritis DAS (cJADAS-10), live births 
and major congenital anomalies. The study included 119 women and 152 pregnancies. The 
largest JIA category was RF-negative polyarthritis (30%). The women were observed 
approximately eight years until conception and all were treated with DMARDs before, 92% 
bDMARDs. 67 pregnancies were exposed to DMARDs early in pregnancy and the median 
treatment length during pregnancy was six weeks. Disease activity was reported to be 
moderate before and during pregnancy and high afterwards when cJADAS-10 was used. 
DAS28CRP was reported to indicate a low mean disease activity before and after 
pregnancy and remission during pregnancy (<2.6), further patients with polyarthritis had 
lower disease activity than patients with enthesitis related arthritis or PsA. Pregnancy 
outcomes were assessed comparing DMARD exposed with DMARD unexposed and 
among live births only haemorrhage differed between the groups with increased frequency 
among unexposed compared to exposed. 
In conclusion, studies regarding JIA and pregnancy outcomes are more common during the 
later years and include larger study populations which is promising. There are indications 
of increased proportions of preterm birth in pregnancies with JIA (13, 39, 51) and some 
studies report increased proportion of caesarean deliveries (13, 45). The comparison of 
studies is hampered by the different outcomes reported. More recent studies focus on 
disease activity and antirheumatic treatment which is very important but comparison of 
these studies are also complicated due to use of different measures of disease activity and 
different time points of assessment. Most studies use variations of DAS28, most suitable 
for RA. Given the heterogeneous presentation of JIA this assessment index may, for 
example be less suitable in the subgroup with enthesitis related arthritis and underestimate 
disease activity. Further, several of the studies are conducted in ongoing prospective 
pregnancy cohorts limiting assessment of disease activity to be based on telephone 
interviews as well as absence of a comparison group. More than one study is based on the 
US-Canadian OTIS Autoimmune Disease in Pregnancy Project where inclusion is 
voluntary which increases the risk of selection bias and may lead to less generalizable 
results. 
2.2.3 Psoriatic arthritis 
Psoriatic arthritis (PsA) is part of the spondylarthritis (SpA) group. This is a heterogeneous 
group of disorders with interrelated features more than distinct diseases, and includes 
ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis (ReA), inflammatory 
bowel disease related arthritis (IBD-SpA) and undifferentiated spondyloarthritis (uSpA). The 
various clinical forms include spinal (axial) features, peripheral arthritis, enthesopathy and 
extra-articular features such as uveitis, psoriasis and inflammatory bowel disease. Studies 
regarding the prevalence of SpA are few, reporting 0.2-1.2% for AS and about double for 
SpA (52, 53). 
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Psoriatic arthritis (PsA) is an inflammatory, seronegative (i.e. not associated with serum 
autoantibodies) arthritis associated with psoriasis (Pso), which is equally common among 
men and women. Pso is a chronic relapsing inflammatory skin disease, characterised by the 
presence of scaling lesions. Age of onset of PsA is typically between 30 and 55 years. PsA 
usually presents with variable patterns of joint and skin involvement and of degree of 
severity. Disease manifestations include a spectrum from mild mono/oligo arthritis to very 
severe, erosive and destructive polyarthritis. Several disease subsets have been defined 
according to joint involvement. For diagnosis of PsA, the CASPAR criteria (classification of 
psoriatic arthritis) have been used since 2006 (Table 2) (54). 
Table 2. The CASPAR criteria for classification of PsA. 
CASPAR criteria 
Requires the presence of inflammatory arthritis (in the joints, spine or enthesites) and ≥3p from the 
following 
At the time of examination 
 Current psoriasis or 2p 
 Prior personal history of psoriasis or 1p 
 Family history of psoriasis 1p 
Nail psoriasis, including onycholysis, pitting and hyperkeratosis 1p 
Absence of rheumatoid factor in blood tests 1p 
Current or prior history of dactylitis 1p 
Radiographic evidence of periarticular new bone formation  
(excluding osteophytes) on x-rays of the hand or foot 
1p 
According to the Swedish association of rheumatology (55), the prevalence of PsA in Sweden 
is 0.2% among adults. The corresponding figure is 2% for Pso, and among those, 15-30% are 
affected by any form of musculoskeletal engagement. 
Both Pso and PsA are associated with co-morbidities including cardiovascular disease 
(CVD), obesity and the metabolic syndrome (56-59), with a corresponding significantly 
increased risk of cardiovascular events (58). The metabolic syndrome describes the presence 
of abdominal obesity, atherogenic dyslipidemia, hypertension, hyperglycaemia, insulin 
resistance, pro-inflammatory and a pro-thrombotic state (60). Studies have shown that the 
metabolic syndrome was equally associated with mild and severe psoriasis, and the 
cardiovascular co-morbidities were found to be equally prevalent in early and established 
PsA (61). Some evidence indicate that obesity may be a risk factor for developing PsA (62) 
based on the assumption that adiposity is associated with inflammatory cytokines known to 
be associated with Pso. Obesity is an independent risk factor for Pso (63). There are also 
studies stating that chronic inflammatory conditions, such as PsA, could be considered as 
independent risk factors for CVD and contribute to the large cardiovascular burden among 
these patients (64-67). EULAR recognises a higher risk of CVD in PsA patients, just as in 
RA and AS patients (68). 
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2.2.3.1 Pregnancy outcomes in PsA pregnancies 
Studies on pregnancy outcomes in PsA are increasing in number (Table 3). 
Table 3. Pregnancy outcomes in women with diagnosis of PsA. 
Author, year Diagnosis N Outcome Conclusion/Result 
Ostensen(69), 1988 PsA 12 
Description of 
disease course 
“PsA followed a pregnancy 
pattern resembling RA” 
Mouyis et.al.(70) 2017 PsA 16 
Disease activity and 
foetal outcomes 
“PsA worsens during pregnancy 
and postpartum” 
Polachek et.al.(71) 2017 PsA 42 Disease activity 
“The outcome of pregnancy 
among patients with PsA is 
excellent” 






Increased risk of gestational 
hypertension, pre-eclampsia and 
elective caesarean delivery 
Strouse et.al(73) 2018 







Increased odds of preterm birth,  
Polachek,(74) 2019 PsA 151 Questionnaire based 
Rate of live birth, vaginal 
delivery, gestational age and birth 
weight were similar compared to 
healthy controls. 
58% reported favorable joint 
activity during pregnancy 
Mörk,(75) 2019 





Non-significant estimates of 
preterm birth, caesarean delivery 
aOR SGA 1.72 (0.98-3.02) 




Disease activity was highest at 6 
months postpartum. Women with 
TNFi had lower disease activity 





Increased risk of moderate 
preterm birth, oligohydramnios, 
caesarean delivery  
A high HAQ score at 32 gw 
associated to preterm birth 
Three of the studies in this table are more descriptive (69-71) and two of them describe the 
outcome disease activity during pregnancy in opposite ways. Mouvis et al. concludes that 
PsA worsens during pregnancy and Polachek et al. concludes that the outcome among 
patients with PsA is excellent. This can be due to the limited number of pregnancies studied. 
However, there are somewhat conflicting results in the other studies as well. The largest 
cohort of PsA pregnancies is studied by Bröms et al. (72) including singleton pregnancies 
with births 2007-2012 from Sweden and Denmark. PsA was a subgroup in a larger cohort of 
Pso pregnancies. They report that women with PsA had increased risks of gestational 
hypertension aOR 1.60, 95% CI and preeclampsia aOR 1.49, 95% CI compared to 
pregnancies without Pso. Further, there was an increased risk of elective caesarean delivery. 
The proportion of preterm birth was 6% among PsA pregnancies compared to 5.4% in the 
non-Pso pregnancies and the PsA subgroup consisted of approximately 63% subsequent 
pregnancies and the comparison group 55%. The analyses were adjusted for parity among 
other confounders. However, the adjusted OR was 1.25, 95% CI 0.94-1.65. 
Both Strouse et al. (73), and Smith et al. report increased risk of moderately preterm birth and 
in the latter study they were able to describe an association of high HAQ score at 32 
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gestational weeks (vs. not) and increased risk of outcome preterm birth (77). As well as in the 
large study by Bröms et al. there were increased risks of caesarean delivery and pre-
eclampsia compared to a comparison group of pregnancies reported by Smith et al. 
In a Danish cohort study of pregnancies with SpA 1997 to 2016 there was an increased risk 
of moderately as well as very preterm birth, elective caesarean delivery, emergency caesarean 
delivery as well as use of epidural analgesia (75). PsA pregnancies were analysed as a 
subgroup, the authors conclude that the prevalence of preterm birth and delivery by caesarean 
were increased for all subtypes of SpA compared to the reference group but least for PsA. No 
information about antirheumatic treatment or disease activity was presented in this study. 
Ursin et al. (76) conducted a prospective study with the aim to study disease activity in 
women with peripheral PsA from pre conception to one year postpartum with the use of 
validated disease activity measures. The methodology is similar to what was described for 
assessing disease activity in JIA, a study by the same author (48). The study included women 
with a diagnosis of PsA 2006-2017 and all women defined as having PsA fulfilled the 
CASPAR criteria. The included women had data from at least one time point in pregnancy. 
The study cohort comprised 108 pregnancies. Mean number of visits per pregnancy was 4.4. 
Disease activity was measured using the 3-variable Disease Activity Score in 28 joints 
(DAS28) using the CRP level (DAS28CRP3). Disease activity categories were defined 
according to EULAR criteria. To assess axial disease activity Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI) was used. BASDAI is calculated from six patient reported 
items and give a final score 0-10 with 10 corresponding to maximal disease activity. Further, 
the assessed activity of psoriasis using the Psoriasis Area and Severity Index (PASI). 
Information about medication was collected at each visit. 
Approximately 75% of the women were in remission or had low disease activity from time 
before pregnancy to one year postpartum even though use of DMARD decreased. The 
authors report variation in disease activity with amelioration in pregnancy and increased 
activity six months postpartum. The trend was the same for axial PsA and activity of psoriasis 
was low. The disease activity increased six months postpartum although TNFi was used of 
40% the women. 
2.2.3.2 Disease activity measures in PsA 
PsA can often affect distal interphalangeal joints and the ankles, (78) and these joints are not 
counted in DAS28. Thus, using that index can underestimate disease activity in PsA. Even so, 
DAS28CRP has been validated and in use for assessing disease activity in PsA (79). In 2010 
the Disease Activity Index for Psoriasis Arthritis (DAPSA) was launched (80). DAPSA is 
more extensive and is calculated from 66 joint count for swelling and 68 joint count for 
tenderness, patient global assessment, patient pain assessment and CRP. Neither DAS28CRP 
nor DAPSA assesses skin involvement, dactylitis, enthesites or axial involvement of the 
disease. 




3 RESEARCH AIMS 
3.1 AIM 
The overall aim of this thesis is to study and describe the influence of inflammatory arthritis 
on pregnancy outcomes. 
3.1.1 Specific aims 
The specific aims are to study: 
 The risk of adverse pregnancy outcomes associated with a history of juvenile JIA 
(Study 1) 
 Whether women with PsA are at increased risk of adverse pregnancy outcomes 
(Study 2) 
 Pregnancy outcomes in women with PsA with respect to presence, timing and type of 
anti-rheumatic treatment as a proxy for disease severity (Study 3) 





4 MATERIALS AND METHODS 
4.1 SETTING 
The studies in this thesis were all conducted in Sweden, where the opportunities to perform 
epidemiological research are eminent due to the structure of the health care system and the 
existence of the unique personal identity number. This number is assigned to each resident at 
birth or immigration and enables linkage between the nationwide registers which hold 
prospectively collected information on health and social factors for all inhabitants. (82) The 
main holders of the registers are the National Board of Health and Welfare and Statistics 
Sweden. An additional type of registers available in Sweden are the quality registers. These 
are established and developed by the medical profession for follow up of quality of care, 
procedures and given treatments. These registers are also utilised for research. Further, health 
care in Sweden is public and tax funded, making it accessible to all residents. In addition, all 
pregnant women are offered free antenatal and delivery care. More than 98% of pregnant 
women attend antenatal care and over 99% of all births take place in hospitals (83). As a 
result of the almost complete coverage of the national registers, study populations can be 
selected in an almost unbiased way. 
4.2 DATA SOURCES USED 
4.2.1 National registers 
4.2.1.1 The National Patient Register 
The National Patient Register (NPR) is kept by the National Board of Health and Welfare and 
consists of the Swedish Inpatient Register and the Swedish Outpatient Register. The NPR 
contains information on hospital discharges by county since 1964 and nationwide since 1987. 
Since 2001, nationwide data from specialist outpatient care (not primary care) are included in 
the register. The coverage is close to 100% for inpatient care and somewhat lower for 
outpatient care, mainly due to lower reporting from private and psychiatric care (84). 
Diagnoses and procedures are coded according to International Classification of Disease 
(ICD) versions 7 through 10. Information from the NPR was used in study I-III. 
4.2.1.2 The Swedish Medical Birth Register 
The Swedish Medical Birth register (MBR) is kept by the National Board of Health and 
Welfare and covers more than 98% of all births in Sweden from 1973 and onwards (85, 86). 
In the register, mothers and their infants are linked. From first attendance at antenatal care 
throughout pregnancy, delivery and the neonatal period, information is collected 
prospectively through structured forms filled out by midwives and physicians. The register 
includes information on identification and demographic data (for example country of birth), 
social factors such as cohabiting with the father, smoking habits and alcohol use, maternal 
medical history, information about pharmacological treatment and current BMI, and 
reproductive history (history of infertility, infertility treatments, number of previous 
pregnancies). During pregnancy, information is continuously added. Delivery characteristics 
such as time of birth, parity, maternal age, onset and mode of delivery, labour analgesia, 
foetal presentation and mode of birth as well as medical conditions and procedures are 
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recorded during delivery or at discharge from the delivery unit. ICD codes 8-10 are used for 
diagnoses. Information about the infant single or multiple birth, live or stillborn, gestational 
age, birth weight, length, sex, Apgar score, malformations and other diagnoses classified 
according to ICD during the neonatal period are also captured in the MBR. Information from 
the MBR was used in study I-IV. 
4.2.1.3 The Prescribed Drug Register 
The Prescribed Drug Register (PDR) contains information on all dispensed prescriptions of 
drugs (amount and dates) classified according to the Anatomical Therapeutic Chemical 
(ATC) classification system from Swedish pharmacies since July 2005 (87). The register 
does not include data on drugs administrated or used in hospitals. Information from the PDR 
was used in study III. 
4.2.1.4 The Swedish Educational Register 
The Swedish Educational Register (ER) is held by Statistics Sweden and contains 
information about the highest level of completed education of all Swedish citizens 16-74 
years of age. Information about foreign-born citizens’ educational level is gathered yearly via 
surveys. Information from the ER was used in study I-III. 
4.2.1.5 The Swedish Total Population Register 
The Swedish Total Population Register (PR) is maintained by Statistics Sweden and holds 
census data since 1968. The register contains data on birth, death, name change, marital 
status, family relationships and migration within Sweden as well as to and from other 
countries (88). Information from the PR was used in study II-IV. 
4.2.2 Quality Registers 
4.2.2.1 The Swedish Rheumatology Quality Register 
The Swedish Rheumatology Quality Register (SRQ) was started in 1995 and is maintained by 
the Swedish Society of Rheumatology. It was originally a clinical quality register of patients 
with RA. With time, it has developed to include also patients with many other rheumatic 
diagnoses, including PsA, with the aim to improve care and treatment. Data is collected 
longitudinally by both care givers (rheumatologists and nurses) and patients. The register 
includes information on diagnosis and disease debut, dates of visits, anti-rheumatic treatment 
and disease activity measures. Since 1999, the SRQ includes the Swedish Biologics Register, 
ARTIS (Antirheumatic Treatment in Sweden) a register for patients with any rheumatic 
disease who start biological treatment. ARTIS was started in collaboration with the Swedish 
Medical Products Agency with the primary aim to evaluate the safety of biologic drugs. The 
coverage in the register of patients with RA, PsA, AS and SpA diagnoses on biologic therapy 
is high, 95% for RA diagnosis and 86% for AS, PsA and SpA (89). Information from SRQ 
was used in study III and IV. 
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4.3 STUDY POPULATIONS AND STUDY DESIGNS 
All studies included in this thesis use pregnancies and births as study subjects, i.e. the 
individual women are not studied. 
Table 4. Overview of study characteristics. 
 Study I Study II Study III Study IV 






-matching variables in the 
main cohort maternal age, 
year of birth and parity 
Register based 
cohort 
Years of delivery 1992-2011 1997-2014 2007-2017 2007-2017 
Data sources MBR, NPR, ER MBR, NPR, PR, ER MBR, NPR, PR, 
ER, PDR, SRQ 
SRQ, MBR 
Number  
of study subjects 

















-Mode of onset of 
labour 
-Mode of delivery 
-Early (0-27days) 
neonatal death 















-Mode of onset of 
labour 
-Mode of delivery 
-Apgar score <7 at 5 
minutes 





















Co variates -BMI 
-Calendar year of 
birth 






-Calendar year of 
birth 






-Calendar year of 
birth 









4.3.1 Study I 
4.3.1.1 Study population in study I 
We identified births from 1992 until 2011 in the MBR and merged this with information from 
the NPR and the ER. After exclusion of multiple births (n=59 259), births with missing or 
invalid personal identity number (n=2434) and births to women with a diagnosis of systemic 
inflammatory and connective tissue diseases (identified via ICD codes versions 8-10) to 
avoid misclassification of the exposure (n=9407), the final study cohort consisted of 
1 951 009 births. 
4.3.1.2 Exposure in study I 
The exposure juvenile onset arthritis was defined according to ICD codes (Table 5) with the 
requirement of at least one listing diagnosis of JIA in inpatient or outpatient care from 
paediatric, paediatric surgery, internal medicine or rheumatology departments before 18 years 
of age. Because the definition of the diagnosis JIA requires debut or disease onset before 16 
years of age, and this does not match the Swedish cut-off age between paediatric and adult 
care which is 18 years of age, we included both those with JIA diagnosis and those with 
diagnoses of PsA, AS, RA and inflammatory spondyloarthritis before 18 years of age. Since 
JIA is a heterogenic condition that may or may not persist into adulthood, we created two 
subgroups of births within the exposed JIA births. The first subgroup was considered to have 
JIA confined to childhood and adolescence and included births to women with onset of JIA 
before 18 years of age or a diagnosis of any of the corresponding adult arthritis diagnoses 
listed in Table 5 before 18 years of age, but without any visit or hospitalisation with any of 
these diagnoses after the age of 18 until delivery. This subgroup was described as “JIA 
paediatric only” (n=1169). The second subgroup included births to women with a diagnosis 
of JIA who also had at least one visit or hospitalisation for a diagnosis of chronic 
inflammatory arthritis after the age of 18 years but before delivery. This group was described 
as “JIA persisting into adulthood” (n=638). 
Table 5. ICD codes used for exposure variable in Study I 







































4.3.1.3 Outcomes in Study I 
Outcomes pre-eclampsia and eclampsia were analysed among all births and were identified 
via ICD 9 codes 642E-G and ICD 10 codes O14- O15. Gestational age at delivery was used 
to categorise pre-eclampsia as early onset (diagnosis and birth before gestational week 34+0) 
or late onset (diagnosis and birth ≥34+0). Also, the outcome stillbirth was analysed among all 
births and defined as intrauterine death after gestational week 28 from 1992 to 30 June 2008 
and after gestational week 22+0 from 1 July 2008. The other outcomes were analysed among 
live births. We assessed preterm birth, defined as birth before 37+0 gestational weeks and 
categorised them into very preterm birth (birth < 32+0 gestational weeks) and moderately 
preterm birth (32+0 to 36+6 gestational weeks). Further, we categorised the preterm births by 
type of onset; spontaneous or medically indicated (induced labour). Onset of labour was 
categorised into spontaneous or induced and mode of delivery into vaginal birth, assisted 
vaginal birth and birth by caesarean section. The latter were categorised as emergency or 
elective (planned). For foetal outcomes we assessed neonatal death (death before 28 days), 
Apgar score <7 at 5 minutes and SGA which was defined as a birth weight of more than two 
SD below the sex-specific mean for gestational age (90). 
4.3.2 Study II 
4.3.2.1 Study population in study II 
We created a study cohort of 41 485 first and subsequent singleton pregnancies with births 
occurring 1997 to 2014. 
These births were identified from an existing linkage where individuals with chronic 
inflammatory diagnoses were identified from NPR and matched to five comparator subjects 
based on age at index person’s diagnosis, calendar year, sex and county. This original linkage 
was also, for example, enriched with information from the ER, MBR and SRQ. 
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Figure 2. Flow chart with schematic information of sampling process and assembling of the 




4.3.2.2 Definitions and descriptions of variables used in study II 
Table 6. Definitions and descriptions of variables used in study II or III. 
Variables used Register 
ICD 10 
code 
Description for the purpose of this study 
Exposure variable 








Requirement of a main diagnosis from inpatient care in 
the department of rheumatology or internal medicine or 
requirement of two separate visits in outpatient care 
with at least one in the department of rheumatology or 
internal medicine. Diagnosis one year before date of 
conception to be considered as exposure. 





One listing at department of rheumatology or internal 
medicine. 
Diagnosis of JIA was allowed before first diagnosis of 
PsA but not after. In that case the birth was considered 
to be non-PsA. 
Ankylosing spondylitis 
(AS) 











Diabetes mellitus type 1 NPR E10 Diagnosis one year before conception to be considered 
as an existing pre pregnancy condition. 
Chronic hypertension NPR I10-I15 Diagnosis one year before conception to be considered 
as an existing pre pregnancy condition. 
Treatment for infertility MBR  Checkbox in the register. 
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One visit in at the department of rheumatology or 
internal medicine. 










One listing at the department of rheumatology or 
internal medicine. 
If a diagnosis of RA occurred before diagnosis of PsA, 
the birth was considered to be non-PsA 
Outcome variables 
Pre-eclampsia MBR O14- 
O15 
The clinical definition of preeclampsia during the study 
period was two blood pressure measurements of 
≥140/90 with at least 4h apart combined with 
proteinuria (≥0.3 grams per 24 h or one or more on a 





Onset of pre-eclampsia and delivery < 34+0 gestational 
weeks (gw) 
Late onset pre-eclampsia MBR O14-
O15 
Onset of pre-eclampsia and delivery ≥ 34+0 gw 
Gestational diabetes NPR O244 New onset diabetes during pregnancy 
Preterm birth MBR  Birth before gw 37+0  
Moderately preterm birth MBR  Births between gw 32+0-36+6 
Very preterm birth MBR  Births between gw 22+0-31+6 
Spontaneous onset of 
preterm birth 
MBR  If gestational age at delivery was preterm and the onset 
of labour was spontaneous or preterm pre-labour rupture 
of membranes (PPROM) the onset was considered 
spontaneous. 
Medically indicated 
onset of preterm birth 
MBR  If the gestational age at delivery was preterm and the 
onset of labour wasn’t spontaneous we considered it 
medically indicated. 
Preterm pre-labour 
rupture of membranes 
(PPROM) 
MBR O42 In conjunction with preterm delivery (gestational age at 
birth) 
Induction of labour MBR O61 Checkbox in the register and ICD code 
Caesarean delivery (all) MBR O82 Both elective and emergency caesarean deliveries 
Elective caesarean 
delivery  
MBR  Planned caesarean delivery before start of labour 
Emergency caesarean 
delivery  
MBR  Not planned caesarean delivery 
Assisted vaginal delivery MBR  Delivery/birth by vacuum extraction or forceps 
Small for gestational age 
(SGA) 
MBR  Birthweight below 2 standard deviations (SD) of sex -
specific mean weight per gestational age 
Large for gestational age 
(LGA) 
MBR  Birthweight above 2 standard deviations (SD) of sex -
specific mean weight per gestational age 
5 min Apgar score <7 MBR   
Neonatal death  MBR  Infant death 0-27 days after birth 
Stillbirth MBR  Non-live birth ≥ 22+0 gw since 1st of July 2008, before 




4.3.2.3 Exposure in study II 
Exposure in this study was PsA, defined with ICD-10 codes L405, M070-1 and M073, as a) a 
main diagnosis from inpatient care at a rheumatology or internal medicine department 1997-
2014 or b) at least two visits in outpatient care with the diagnosis of PsA at a rheumatology or 
internal medicine department 2001-2014. First singleton pregnancies after 1997, and 
subsequent pregnancies, with this exposure were identified in the existing linkage. If time 
from diagnosis of PsA and delivery was less than one year, the pregnancy was excluded. 
Also, pregnancies with a diagnosis of SLE or RA before birth (Figure 2) were excluded. 
Unexposed pregnancies and births were identified as all of the matched population 
comparator persons’ pregnancies regardless if they were sampled originally as a comparator 
for another inflammatory arthritis diagnosis than PsA. In theory, all of the population 
comparator births had the possibility to change group and be exposed during the study period, 
if the sampled comparator individual was diagnosed with PsA. 
4.3.2.4 Outcomes in study II 
Outcomes pre-eclampsia and eclampsia were identified via ICD-10 codes O14- O15 and 
analysed among all births. Gestational age at delivery was used to categorise pre-eclampsia as 
early onset (diagnosis and birth before gestational week 34+0) or late onset (diagnosis and 
birth ≥34+0). The outcome stillbirth was defined as intrauterine death after gestational week 
28 from 1992 to 30 June 2008 and after gestational week 22+0 from 1 July 2008. Gestational 
diabetes was identified via ICD-10 code O24.4 as new onset diabetes during pregnancy. The 
other outcomes were analysed among live births. We assessed preterm birth, defined as birth 
before 37+0 gestational weeks and categorised them into very preterm birth (birth <32+0 
gestational weeks) and moderately preterm birth (32+0 to 36+6 gestational weeks). Further, 
we assessed preterm pre labour rupture of membranes (PPROM) and we categorised the 
preterm births by type of onset; spontaneous or medically indicated. Onset of labour was 
categorised into spontaneous, induced or by elective caesarean delivery. Mode of delivery 
was categorised into vaginal birth, assisted vaginal birth and birth by caesarean delivery. The 
latter were categorised as emergency or elective (planned). For foetal outcomes we assessed 
Apgar score <7 at 5 minutes, SGA birth, large for gestational age (LGA) birth and neonatal 
death (death before 28 days). 
4.3.3 Study III 
4.3.3.1 Study population in study III 
We assembled a study cohort of 10 131 singleton pregnancies with births in the study period 
1 April 2007 to 31 December 2017. The start of the study period was selected to enable 
inclusion of data from the PDR. 
The study cohort was sampled in the same way as described in Figure 2/study II but with an 
updated linkage including information on births until 31 December 2017. In this study cohort, 
we identified 921 exposed pregnancies and matched them to 10 unexposed pregnancies based 
on year of birth, maternal age and parity. 
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4.3.3.2 Exposure(s) in study III 
The main exposure was diagnosis of PsA, identified with an ICD-10 code of L405, M070-1 
or M073 in NPR, with at least two listings/visits with this diagnosis, at least one being at the 
department of rheumatology or internal medicine. Furthermore, the diagnosis had to have 
been present at least one year before start of pregnancy. 
We used presence, timing and type of antirheumatic treatment as a proxy for PsA disease 
severity and assessed this in several subgroups where we stratified the exposure to diagnosis 
with or without different types of antirheumatic treatment in different pre-specified time 
frames of each pregnancy. 
Figure 3. Flow chart showing different stratified analysis groups in study III with 
pregnancies based on presence, timing and type of antirheumatic treatment. 
 
The PDR holds information on all filled prescriptions at Swedish pharmacies since July 2005, 
including date of dispensing and the ATC code indicating the drugs. For this study, we 
defined antirheumatic treatment as oral corticosteroids, conventional (c) or biological (b) 
disease modifying antirheumatic drugs (DMARDs). ATC codes were used to identify 
antirheumatic treatment (Table 7). One filled prescription in the PDR in the pre-specified 
time frames (from one year before the start of pregnancy to delivery) was considered as 
treatment. As the PDR does not include data on drugs administrated in day-care units in 
hospitals, we retrieved information on infusion of infliximab from the Swedish 
Rheumatology Quality Register (SRQ). 
 
26 
Table 7. ATC codes used to identify antirheumatic treatment in study III. 
ATC codes used to identify anti-rheumatic treatment 
Oral corticosteroids H02AB01,-04,-06,-07 
Conventional synthetic disease modifying drug 
(cDMARD) 
A07EC01,-05, L04AA13, L04AD01, L04AX01, 
L01BB01, L01BA01, L04AX03, M01CB01, 
M01CB3, P01BA01, P01BA02, L04AAD02, 
L04AA06 and M01CC01 
Biological DMARDs (bDMARD) L04AB01, L04AB04, L04AB05, L04AB06, 
L01XC02, L04AA24, L04AC03 and L04AC07 
To arrive at the different restricted subgroups of pregnancies based on presence and timing of 
antirheumatic treatment, we first divided the 921 PsA pregnancies into 495 pregnancies 
without any treatment from one year before pregnancy until delivery and 426 PsA 
pregnancies with any antirheumatic treatment in the same time frame (Figure 3). The latter 
pregnancies included 19 pregnancies with no treatment before, but treatment only during 
pregnancy and 407 pregnancies with treatment in the year before pregnancy irrespectively of 
treatment during pregnancy. These 407 pregnancies were further stratified into 170 
pregnancies with treatment only in the year before pregnancy (no treatment during 
pregnancy) and 237 pregnancies with treatment both in the year before and during pregnancy. 
Finally, the 19 pregnancies with treatment only during pregnancy were added to the 237 
pregnancies with treatment both before and during pregnancy resulting in the last stratified 
group with 256 pregnancies with antirheumatic treatment during pregnancy. 
4.3.3.3 Outcomes in study III 
We used ICD-10 codes to identify pre-pregnancy co-morbidities, such as hypertension and 
diabetes mellitus type, as well as outcomes including pre-eclampsia (including eclampsia 
O14-O15), gestational diabetes (O244) and gestational hypertension (O13). Gestational age 
was estimated by ultrasonography or, if ultrasonography was unavailable, by the recorded 
date of the first day of the last menstrual period. 
Preterm birth was defined as birth before 37 completed weeks of gestation (gw) and further 
sub-categorised into moderately preterm birth (32+0 to 36+6 gw) or very preterm birth (22+0 
to 31+6 gw). We sub-categorised preterm birth by onset (spontaneous or medically 
indicated). Further caesarean deliveries were sub-categorised into emergency or elective. For 
outcomes in the neonates we assessed SGA and LGA. 
4.3.4 Study IV 
4.3.4.1 Study population in study IV 
The study cohort consisted of 211 singleton pregnancies resulting in a live birth from 
1 January 2007 to 31 December 2017 with a maternal diagnosis of psoriatic arthritis (n=189) 
or juvenile psoriatic arthritis (n=22). 
We defined maternal PsA as all women in the SRQ registered with the diagnosis PsA (or 
juvenile psoriatic arthritis) by their treating rheumatologist. 
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The study period of interest for each individual pregnancy was from one year before the start 
of pregnancy until the time point of delivery. This time period was divided into three month 
strata starting one year before date of conception and ending at the time point of delivery. The 
last stratum could thus be of different length for different pregnancies, because a pregnancy 
with a term birth can last from 259 to 294 days, i.e. a difference of more than a month. 
4.3.4.2 Exposure in study IV 
The exposure was measures of disease activity, DAS28CRP and HAQ, retrieved from SRQ. 
A DAS28CRP of ≥3.2, corresponding to moderate to high disease activity, and/or a HAQ 
score of >0.5 was considered as active PsA disease. 
Pregnancies identified in SRQ but without registrations of disease activity during the time 
period of interest in this study were kept in the cohort for comparison, even though they were 
considered unexposed. 
We identified 110 pregnancies, corresponding to 52% of the study population, with at least 
one registered DAS28CRP value during the study period. Among these 110 pregnancies, 46 
had a registered DAS28CRP ≥3.2 at any time (i.e. from one year before start of pregnancy 
until birth) and 64 pregnancies had a registered DAS28CRP <3.2 (and no registered 
DAS28CRP values ≥3.2 during the study period) 101 of the 211 pregnancies in the study 
population did not have a registered value on DAS28CRP during the study period. 
Regarding HAQ, we identified 118 pregnancies with a registered HAQ score during the study 
period. Of these, 62 pregnancies had registered a score of >0.5, and 56 pregnancies had 
registered values ≤0.5. 93 of the 211 pregnancies did not have any registered HAQ score 
during the study period. 
4.3.4.3 Outcome in study IV 
The outcome of interest in this study was proportion of preterm birth in relation to registered 
high vs. low disease activity. Preterm birth was defined as a birth before 37 completed weeks 




4.4 STATISTICAL ANALYSES 
4.4.1 Statistical methods 
4.4.1.1 Chi-squared test, Fisher’s exact test and Wilcoxon two sample test 
A chi-square (χ2) test is used to determine whether there is a statistically significant difference 
between the expected and observed frequencies in one or more categories in a contingency 
table where the observations are classified in two mutually exclusive classes. 
Fisher’s exact test is a statistical significance test used in the analysis of contingency tables 
and is equivalent to the chi-square test but can be used even if the expected cell count is 
below five. The p-value from the test is computed as if the margins of the table are fixed. 
Wilcoxon two sample test, also named Wilcoxon-Mann-Whitney is a non-parametric test that 
can be used when the variables not are normally distributed. 
4.4.1.2 Logistic regression 
Logistic regression analysis is used to determine the statistical relationship or association 
between one or more independent (predictor or explanatory) variable(s) and a dependent 
(outcome) variable. In a binary logistic regression, the dependent variable is dichotomous in 
two mutually exclusive levels (yes/no). The independent variable can be dichotomous, 
categorical or continuous. To model a linear relationship, the dependent variable is 
transformed by the logit function. The results of a logistic regression are presented as an odds 
ratio (OR) for which confidence intervals may be estimated. With a rare outcome (as a rule of 
thumb when the outcome is below 10%) the OR approximates a risk ratio (RR), the so called 
“rare disease assumption”. For more common outcomes, the OR overstates the relative risk. 
4.4.1.3 Other regression models 
Even though binary outcomes are often analysed with a logistic regression model to obtain 
ORs, there may be situations, for example with a common outcome, where it would be 
desirable to estimate a RR instead. Typically, in such cases, a log binomial regression model 
is proposed. The difference from a logistic regression model is the link between the 
independent variable and the probability of the outcome. For logistic regression, the logit link 
is used, whereas for log binomial it is the log link which is used. Apart from this, both models 
assume that the error terms have a binomial distribution. The log binomial model may give 
narrower confidence intervals than what is true. Furthermore, this model may have 
difficulties to converge (91). If so, a Poisson regression model with a robust error variance 
can be used. The Poisson regression model assumes a Poisson distribution for the outcome, 
i.e. the occurrence of an outcome is equally likely at any point in time, and the probability of 
an outcome occurring is proportional to the length of time you wait. Initially, the model was 
recommended for studies of rare diseases where patients may be followed for different 
lengths of time. However, the model can be used with a time-at-risk value specified as 1 for 
each subject. The recommendation of using robust variance estimates originates from the 
observation that if you do not, the model estimates too wide confidence intervals (92, 93). 
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4.4.1.4 Generalised estimating equation 
The generalised estimating equation (GEE) is used to account for correlation between 
dependent observations in a study population. GEE estimates population averaged model 
parameters and their standard errors. 
4.4.1.5 Multiple imputation 
Missing data is common, as there will be values missing in almost every dataset or source. 
When using regression models, the analyses will be performed on complete cases, i.e. the 
model only uses those observations for which information is complete. This can reduce 
statistical power and also result in biased estimates. Data can be missing for different reasons; 
1) missing completely at random (MCAR) 2) missing at random (MAR) and 3) missing not at 
random (MNAR). Different types of missing data require different treatment. Multiple 
imputation, one method to handle missing data, generally assumes that the data are at least 
MAR, but this procedure can also be used if data is MCAR. The purpose when addressing 
missing data is to reproduce the variance/covariance matrix which would have been observed 
if no information was missing from the data. Multiple imputation is a general approach to 
missing data which aims to allow for the uncertainty about the missing data by creating 
several different plausible imputed data sets and combining results obtained from each of 
them. There are several steps in the procedure. First, the imputed values are sampled from the 
predicted distribution based on the observed data. The imputed values replace the missing 
values in several copies of the data set. Second, a statistical model is fitted to the imputed 
sets; in these, the estimated associations will differ according to the variation in the 
imputation of the missing values. They are averaged to give overall estimated associations. 
4.4.1.6 Interaction analysis 
An interaction analysis is conducted to estimate the possible effect modification of an 
interaction variable. A significant interaction indicates that the effect of one independent 
variable on the outcome variable varies at different values of the other independent variable. 
Interaction may be tested by adding the interaction term to a regression model. 
All analyses included in this thesis were performed using SAS software version 9.4. 
4.4.2 Statistical methods and sensitivity analyses used in study I-IV 
4.4.2.1 Study I 
In study I, we assessed differences between births in mothers with JIA and the reference 
population with regards to categorical data, by a χ2 test where p<0.05 was considered 
statistically significant. 
Unconditional logistic regression analyses were performed to estimate crude and adjusted 
ORs (aORs) with associated 95% CIs for outcome variables. The GEE method was used in 
the model to account for the clustering due to the inclusion of multiple births from the same 
mother. In the adjusted analyses, we adjusted for possible confounders that is maternal age at 
delivery, parity, BMI, smoking habits, educational level, the mother’s country of birth and 
calendar year of birth. 
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We used a formal interaction test in the model to estimate possible effect modification 
between the exposure status*diabetes on the outcome pre-eclampsia. Several sensitivity 
analyses were performed. In the first sensitivity analysis, we redefined exposure to increase 
validity and decrease risk of misclassification of exposure by requirement of two listings or 
visits with diagnoses of JIA or corresponding arthritis diagnoses before the age of 18. We 
performed separate analyses for JIA paediatric and persisting. In the second sensitivity 
analysis, we restricted the analysis to births occurring 2002-2011 to assess if there existed 
possible calendar time dependent changes of care, both in obstetrics and rheumatology, which 
affected the estimates. To further assess possible effects of calendar time and changes in care 
procedures, we restricted a third analysis to births identified during the years 1987-2011 
when ICD-9 and ICD-10 codes were in use. In a fourth sensitivity analysis, we performed an 
analysis restricted to births with JIA paediatric from 2003 and onwards with a requirement of 
at least two years from last diagnosis until delivery. This was to ensure that we did not 
misclassify a birth as JIA paediatric when it should be defined as JIA persisting into 
adulthood. Because the out-patient part of NPR is available since 2001 and more women may 
have listings in out-patient care than in in-patient care, we assumed that this could influence 
our analysis. 
4.4.2.2 Study II 
In study II, we assessed differences in maternal characteristics between exposed and 
unexposed births by a χ2 test or Fischer’s exact test. Furthermore, we estimated crude and 
adjusted ORs with estimated 95% CI for the outcome variables using a generalised linear 
regression model and a GEE method, with the mother’s identification as a cluster and 
assuming an exchangeable correlation structure. This model provided the best (smallest) QIC 
(quasi-likelihood under the independence model criterion) value when we selected statistical 
model (negative binomial, logistic regression model, Poisson regression model). 
In the adjusted analysis, we used several covariates: country of birth categorised into Nordic 
and non-Nordic, educational level categorised as ≤12 years or >12 years, smoking status as 
self-reported information from first antenatal visit categorised into smoker or non-smoker, 
parity (except in the sensitivity analysis of parity) as primiparous or parous, maternal age 
categorised into 13-24, 25-29, 30-34 and >35 years of age, calendar year of birth categorised 
in 1997-2002, 2003-2008 and 2009-2014. Further, BMI calculated from measured weight and 
self-reported height at the first antenatal visit and categorised as underweight (<18.5 kg/m2), 
normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (≥ 30 kg/m2). 
Because BMI is associated with both exposure and outcome, it could be treated as a 
confounder. However, there are reports that state that weight gain can be an effect of an 
inflammatory condition (94) or other factors (95), so we estimated ORs both with and 
without adjustment for BMI. 
We performed both a complete case analysis and an analysis were variables with missing 
information were imputed using multiple imputation. The missing information were imputed 
in the following order: education, country of birth, preterm birth, low Apgar score (Apgar 
score <7 at 5 minutes), small or large for gestational age, smoking status and BMI category. 
Education was imputed using the variables PsA status, maternal age, parity, gestational 
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diabetes, mode of delivery, pre-eclampsia and neonatal death as predictors. In the following 
imputation steps, all the variables previously imputed were additionally included as 
predictors. Fifty imputed data sets were created and analysed by logistic regression applying 
the GEE method when estimating parameters and co-variance matrices. These were analysed 
by the procedure MIANALYZE in SAS software version 9.4. 
We performed several sensitivity analyses: a) an analysis restricted to first pregnancies, b) an 
analysis restricted to subsequent pregnancies, c) analyses restricted to pregnancies without 
ankylosing spondylitis, inflammatory bowel disease or rheumatoid arthritis before pregnancy 
and d) complete case analysis for comparison. 
4.4.2.3 Study III 
Baseline pregnancy characteristics were presented and calculated as counts and percentages. 
Odds ratios were estimated using a generalized model with logit link and assumption of 
binominal distribution as crude and adjusted odds ratios (ORs), with associated 95% 
confidence intervals. The analyses were performed on individual pregnancies. Because one 
woman could contribute more than one pregnancy, we used the GEE method with mother’s 
identification as a cluster assuming an exchangeable correlation structure. 
No risk estimates were calculated for outcomes with fewer than five events. Statistical 
interaction was assessed by inclusion of the interaction term exposure status (PsA)*parity. As 
the interaction term was significant for the outcome preterm birth, the analyses regarding this 
outcome were stratified on parity. 
All analyses were performed on complete data. 
Adjustments in the main analysis were made for the highest attained level of education, 
smoking status, BMI and country of birth. In the stratified analyses, the matching was broken 
and adjustment for maternal age, year of birth and parity was made in addition. 
4.4.2.4 Study IV 
Maternal characteristics were presented with counts and frequencies for categorical variables 
and medians with corresponding inter-quartile ranges for continuous variables. We assessed 
differences with Wilcoxon two-sample test in the continuous variables (values of DAS28CRP 
and HAQ), and used Fisher’s exact test or χ2 test for categorical variables. A p-value <0.05 
was considered as indicating statistical significance. 
4.5 ETHICAL CONSIDERATIONS 
The main ethical concern in register-based research is to maintain the personal integrity of the 
study subjects. Generally, when research involves human subjects, informed consent should 
be obtained from each study subject. In practice, it is not possible to collect informed consent 
from the usually large number of subjects included in register-based studies. This is also the 
case for the studies included in this thesis. According to the Swedish Ethical Review Act 
(2003:460), research without informed consent from study subjects can be conducted if the 
results could be beneficial for the study subject or for others with the same condition (Ethical 
Review Act, 21 §). The results of the studies included in this thesis will hopefully contribute 
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to increased knowledge about inflammatory arthritis and pregnancy outcomes, which can be 
implemented in clinical praxis and be beneficial in the future. 
Furthermore, the anonymity of the study subjects must be ensured and the handling of 
personal information is regulated in the Swedish Personal Data Act (PUL [SFS 1998:204]). 
The personal identification number of the study subjects included in register-based studies 
(also for the studies in this thesis) has been replaced with a random number by the National 





5.1 STUDY I 
5.1.1 Summary of main findings in study I 
Juvenile onset arthritis is associated with adverse pregnancy outcomes compared to 
population controls. We have identified increased risks of preeclampsia and preterm birth, as 
well as increased proportions of labour induction and caesarean deliveries. 
5.1.2 Main results in study I 
We identified 1807 singleton births in women with a diagnosis of JIA before delivery and 
1 949 202 population comparator births during the study period 1992-2011. The births were 
stratified as JIA paediatric only n=1169 and JIA persisting into adulthood n=638. Regarding 
maternal characteristics, there were differences between the exposed and unexposed births. 
The women with JIA were younger, more often had births later in the study period, were to a 
larger extent born in a Nordic country, had underweight, lower educational level and were 
more frequently smokers. In the analysis of pregnancy outcomes, there were generally 
stronger associations with increased aORs in the JIA persisting into adulthood group 
compared to population comparator births. Regardless of how the exposure was defined or 
how the time frame in which the birth was assessed, we did not find any increased risk of 
stillbirth, early neonatal death or Apgar score <5 in any of the analyses. In the analyses we 
adjusted for maternal age, parity, BMI, calendar year of birth, smoking habits, highest 
attained educational level and the mother’s country of birth. 
5.1.3 Analyses in the subgroup JIA paediatric only 
When we analysed births in women with JIA paediatric only compared with population 
comparator births there were increased risks of preterm birth, moderately preterm birth and 
medically indicated preterm birth aOR 1.32, 95%CI 1.00-1.76, aOR 1.43, 95%CI 1.07-1.91 
and aOR 1.74, 95%CI 1.35-2.67 respectively. Further, induction of labour was more common 
aOR 1.45, 95%CI 1.18-1.77 as well as birth by caesarean delivery aOR 1.42, 95%CI 1.66-
1.73. Both risk of emergency and elective caesarean delivery was increased with aOR 1.37, 
95%CI 1.08-1.74 and aOR 1.39, 95%CI 1.08-1.78 respectively. There were no statistically 
significant increased risks of pre-eclampsia, spontaneous onset preterm birth, assisted vaginal 
delivery, Apgar score <7 at 5 minutes, SGA, LGA, stillbirth or early neonatal death (death 0-
27 days) compared to population comparator births. 
When we required two visits or hospitalisations with ICD code to fulfil the exposure criteria 
of JIA, the number of identified pregnancies were reduced, as expected, n=507. Generally, 
the point estimates were lower and did not remain statistically significant. In this analysis 
only the aOR for caesarean delivery was significantly increased compared to population 
comparator births. 
In the third sensitivity analysis where only ICD-9 and ICD-10 codes were used for definition 
of the exposure n=379, the pattern of increased risks was almost the same as in the main 
analysis. The exception was that medically indicated preterm birth aOR 1.67 95% CI 0.72-
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3.88 did not reach statistical significance, and neither did elective caesarean delivery. The 
point estimates for preterm birth and moderately preterm birth were somewhat more 
pronounced than in the main analysis, aOR 1.67, 95% CI 1.06-2.63 and aOR 1.89, 95%CI 
1.20-2.89 respectively. 
Furthermore, an analysis of the main exposure was made with a restriction to births 2002-
2011 in order to better capture visits before pregnancy in the outpatient register n=636. This 
birth cohort was thought to reflect a different patient population than an inpatient defined 
exposure, as well as a more contemporary cohort of births. In this analysis, we noted the same 
pattern of increased risks as in the main analysis. 
5.1.4 Analyses in the subgroup JIA persisting into adulthood 
Births to women with JIA persisting into adulthood had increased risk of pre-eclampsia aOR 
2.31, 95% CI 1.61-3.32. When the outcome pre-eclampsia was stratified into early onset, 
defined as diagnosis and birth before 34+0 gestational weeks, or late onset defined as 
diagnosis and birth ≥34+0 gestational weeks, both ORs were significantly increased 
compared to population comparator births. The aOR for early onset pre-eclampsia was 6.28 
with 95% CI 2.86-13.81 and was based on a small number (n=9) of pregnancies with the 
outcome in the exposed group. Increased risk of late onset pre-eclampsia was also observed 
aOR 1.96, 95% CI 1.31-2.91. 
When we required two visits or hospitalisations with correct diagnostic code to fulfil the 
exposure criteria of JIA, the point estimates were almost the same as in the main subgroup 
analysis (Table 8). 
In the second sensitivity analysis where we restricted the exposure to those with a diagnosis 
from ICD-9 and ICD-10, the results resembled those of the main analysis with the exception 
of the outcome very preterm birth which was not statistically significant (Table 8). 
In a third sensitivity analysis of births to women with JIA persisting into adulthood with 




Table 8. Adjusted* ORs with 95% CI in the subgroup JIA persisting into adulthood 





Restricted to 2 
diagnoses <18 









 aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) 
All births     
Pre-eclampsia 2.31 (1.61-3.32) 2.39 (1.58-3.62) 2.24 (1.45-3.45) 2.38 (1.60-3.54) 
Early onset pre-
eclampsia** 
6.28 (2.86-13.81) 6.52 (2.55-16.69) 4.50 (1.67-12.14) 4.07 (1.51-10.99) 
Late onset pre-
eclampsia*** 
1.96 (1.31-2.91) 2.04 (1.30-3.18) 2.03 (1.27-3.25) 2.23 (1.31-2.91) 
Live births     
Preterm delivery  
(<37+0 gw) 
2.40 (1.81-3.18) 2.38 (1.70-3.32) 2.37 (1.69-3.34) 2.21 (1.59-3.06) 
Moderately pre-
term delivery 
2.27 (1.68-3.08) 2.07 (1.42-3.00) 2.36 (1.64-3.40) 2.10 (1.47-2.99) 
Very preterm 
delivery 
3.14 (1.58-6.24) 4.42 (2.22-8.81) 2.31 (0.96-5.61) 2.85 (1.35-6.03) 
Preterm delivery, 
medically indicated 
4.12 (2.76-6.15) 5.07 (3.28-7.84) 4.10 (2.52-6.68) 3.94 (2.48-6.25) 
Preterm delivery, 
spontaneous  
1.63 (1.11-2.39) 1.28 (0.78-2.11) 1.65 (1.04-2.61) 1.48 (0.95-2.31) 
Induction of labour 1.37 (1.07-1.75) 1.51 (1.13-2.00) 1.42 (1.06-1.90) 1.36 (1.03-1.79) 
Assisted vaginal 
delivery 
0.97 (0.68-1.38) 0.89 (0.58-1.38) 1.00 (0.67-1.48) 0.99 (0.68-1.45) 
Caesarean delivery 2.47 (1.99-3.08) 2.63 (2.03-3.39) 2.08 (1.60-2.71) 2.17 (1.70-2.77) 
Elective caesarean 
delivery 
3.01 (2.32-3.90) 3.28 (2.45-4.39) 2.19 (1.55-3.09) 2.46 (1.83-3.31) 
Emergency 
caesarean delivery 
1.57 (1.19-2.08) 1.60 (1.15-2.23) 1.73 (1.24-2.41) 1.57 (1.15-2.13) 
SGA 1.84 (1.19-2.85) 2.02 (1.23-3.32) 1.60 (0.96-2.69) 1.70 (1.02-2.85) 
*Adjusted for maternal age at delivery, parity, BMI, calendar year of birth, smoking habits, educational 
level and the mother’s country of birth. 
5.1.5 Analyses of proportions of pre-eclampsia by adverse outcomes 
Since several of the obstetrical outcomes can be interrelated and depend on each other, we 
estimated the proportion of pre-eclampsia in selected adverse outcomes stratified by subgroup 
of JIA compared to population comparator births (Table 9). In births with JIA paediatric only, 
there were no apparent differences in the proportion of pre-eclampsia in exposed vs. 
unexposed births regarding the adverse outcomes. In births with JIA persisting into adulthood 
there were generally higher percentages with pre-eclampsia in the exposed vs. unexposed 
births. In medically indicated preterm births, 45.5% had a diagnosis of pre-eclampsia 
compared to 36.6% of the unexposed births. Furthermore, 32% of the SGA births were 
affected by pre-eclampsia in the exposed group, compared to 14% in the unexposed. Among 
the adverse outcomes caesarean delivery and elective caesarean delivery, the differences were 
smaller; 11.3% vs. 7.2% and 13.3% vs. 7.9% respectively. 
 
36 
Table 9. Proportions of pre-eclampsia by adverse outcomes in births with JIA paediatric 
only compared to population comparator births and JIA persisting into adulthood 
compared with population comparator births. 
 JIA paediatric only JIA persisting into adulthood 
Pre-eclampsia No n (%) Yes n (%) No n (%) Yes n (%) 
 Preterm birth (n=96 492) 
No n (%) 84 500 (87.6) 61 (88.4) 84 507 (87.6) 54 (77.1) 
Yes n (%) 11 923 (12.4) 8 (11.6) 11 915 (12.4) 16 (22.9) 
 Medically indicated preterm birth (n=29 072) 
No n (%) 18 415 (63.4) 18 (69.2) 18 415 (63.4) 18 (54.6) 
Yes n (%) 10 631 (36.6) 8 (30.8) 10 624 (36.6) 15 (45.5) 
 Caesarean delivery (n=280 182) 
No n (%) 259 909 (92.8) 181 (91.4) 259 925 (92.8) 165 (88.7) 
Yes n (%) 20 075 (7.2) 17 (8.6) 20 071 (7.2) 21 (11.3) 
 Elective Caesarean delivery (n=134 427) 
No n (%) 123 752 (92.1) 87 (92.6) 123 741(92.1) 98 (86.7) 
Yes n (%) 10 581 (7.9) 7 (7.5) 10 573 (7.9) 15 (13.3) 
 SGA birth (n=50 713) 
No n (%) 43 413 (85.7) 23 (88.5) 43 417 (85.7) 19 (67.9) 
Yes n (%) 7274 (14.4) 3 (11.5) 7268 (14.3) 9 (32.1) 
The reference groups (population comparators) include all births without JIA paediatric only and JIA 
persisting into adulthood respectively. 
5.2 STUDY II 
5.2.1 Summary of main findings in study II 
Pregnancies with exposure of PsA are associated with increased risks of preterm birth and 
caesarean delivery. Risk of preterm birth differed by parity, where subsequent pregnancies 
did not have an increased risk compared to non-PsA pregnancies. 
5.2.2 Main results in study II 
We identified 541 singleton pregnancies in 330 women with a diagnosis of PsA, and 40 944 
pregnancies in 25 594 women without a diagnosis of PsA during the study period 1997-2014. 
In comparison to non-PsA pregnancies, the PsA pregnancies had higher frequencies of co-
morbidities such as IBD, affecting 2.8% of the PsA pregnancies compared to 0.9% of the 
non-PsA pregnancies, AS 2.0% among PsA pregnancies vs. < 0.01% in non-PsA pregnancies 
and RA 5.9% vs. 0.02%. Pre-pregnancy hypertension was more common in PsA pregnancies 
vs. non-PsA pregnancies: 0.4% vs. 0.1%, thus the absolute number was low (n=2) among the 
PsA pregnancies. This was likewise true for pre-pregnancy type 1 diabetes mellitus, (n=5) 
among PsA pregnancies corresponding to 0.9% compared to 0.4% among non-PsA 
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pregnancies. Furthermore, the women with PsA were more obese, more often smokers and 
more frequently born in the Nordic countries. 
Overall, there was an increased risk of preterm birth among PsA pregnancies vs. non-PsA 
pregnancies, aOR 1.63; 95% CI 1.17-2.28, both with spontaneous onset, aOR 1.51; 95% CI 
1.01-2.24 and medically indicated, aOR 1.85; 95% CI 1.04-3.27. The risk of moderately 
preterm birth was increased whereas very preterm birth was not. PsA pregnancies likewise 
had an increased risk of caesarean delivery, aOR 1.52; 95% CI 1.21-1.91 and risks of both 
emergency and elective caesareans were increased aOR 1.43; 95% CI 1.08-1.88 and aOR 
1.47; 95% CI 1.10-1.97 respectively. There were no increased risks of pre-eclampsia, 
gestational diabetes, PPROM, SGA or LGA. Neither stillbirth, Apgar score <7 at 5 minutes 
or neonatal death. 
Full adjustment, for year of birth, maternal age, parity, smoking, the mother’s country of birth 
and educational level, including also BMI did affect the point estimates to some extent 
regarding pre‐eclampsia aOR 1.21; 95% CI 0.78–1.88 in the fully adjusted model compared 
with aOR 1.33; 95% CI 0.86–2.05, gestational diabetes aOR 1.26; 95% CI 0.54–2.94 in the 
fully adjusted model compared with aOR 1.53; 95% CI 0.66–3.56 and LGA aOR 1.18; 95% 
CI 0.70–1.97 in the fully adjusted model compared with aOR 1.30; 95% CI 0.78–2.17. Full 




5.2.3 Effect of parity 
When we analysed first and subsequent pregnancies separately, the risk of preterm birth was 
exclusively increased in first but not in subsequent pregnancies (Table 10). Conversely, risk 
of emergency caesarean delivery was significantly increased in subsequent, but not in first 
PsA pregnancies vs. subsequent non-PsA pregnancies. 
Table 10. Comparison of selected outcomes stratified in first and subsequent 
pregnancies. 











All births n (%) n (%) 
aOR* 
(95% CI) 





5 (1.5) 239 (0.9) 1.53 (0.62-3.77) 1 (0.5) 119 (0.8)  
Live births n=328 n=25 497  n=209 n=15 183  
Preterm birth 
<37 gw 
35 (10.7) 1461 (5.7) 1.90 (1.33-2.72) 6 (2.8) 533 (3.5) 0.83 (0.36-1.90) 
Spontaneous 
preterm birth 




10 (3.0) 393 (1.5) 1.89 (1.00-3.59) 3 (1.4) 128 (0.8)  
Very 
preterm birth 
< 32 gw 































51 (17.3) 3267(13.8) 1.25 (0.92-1.71) 23 (12.6) 792 (5.8) 2.21 (1.40-3.48) 
*Adjusted for year of birth, maternal age, parity, smoking, the mother’s country of birth, educational level 
and BMI 




5.2.4 Assessment of effect of co-morbidities and RA 
Because co-morbidities and conditions associated with a diagnosis of PsA were more 
common, as expected, in the group of PsA pregnancies, we performed a sensitivity analysis 
in which pregnancies with a diagnosis of IBD, AS or RA before delivery were excluded. 
There were 483 PsA pregnancies in this analysis, compared to 40 499 non-PsA pregnancies. 
The proportion of preterm birth among PsA pregnancies was 7.4% compared to 7.6% in the 
main analysis and aOR of preterm birth compared to non-PsA pregnancies was 1.59; 95% CI 
1.09-2.32 which was substantially the same as in the main analysis. Spontaneous preterm 
birth occurred in 4.8% of the PsA pregnancies in the restricted group compared to 5.2% in the 
main analysis. The ORs for spontaneous and medically indicated preterm birth were not 
statistically significantly increased in the restricted analyses, aOR 1.40; 95% CI 0.89-2.19 
and 1.88; 95% CI 0.94-3.75 respectively. The aOR for caesarean delivery in the restricted 
analysis was 1.41; 95%CI 1.08-1.84, that is largely the same as in the main analysis (aOR 
1.52; 95% CI 1.21-1.91). In the restricted analysis, the aOR for elective caesarean delivery 
was 1.28, 95% CI 0.90-1.82 vs. 1.47, 95% CI 1.10-1.97 in the main analysis indicating that 
the increased risk seen in the main analysis were due to factors carried by pregnancies with 
either co-morbidities or RA. The aORs for emergency caesarean were comparable 1.44; 95% 
CI 1.05-1.98 in the restricted analysis and 1.43; 95% CI 1.08-1.88 in the main analysis. 
5.3 STUDY III 
5.3.1 Summary of main findings in study III 
PsA pregnancies are associated with increased risk of preterm birth compared to non-PsA 
pregnancies as well as caesarean deliveries. The risks differ by presence, timing and type of 
antirheumatic treatment as well as with parity. Most increased risk for preterm birth were 
noted in pregnancies with bDMARD treatment during pregnancy; aOR 4.49 95% CI 2.60-
7.79. 
5.3.2 Main results study in study III 
In the matched main analysis of 921 PsA pregnancies compared to 9210 non-PsA 
pregnancies, the characteristics of women with PsA differed from non-PsA women regarding 
country of birth, where PsA women more often were born in the Nordic countries. 
Furthermore, PsA women were more obese (19.9% vs. 12.6%), more likely to be smokers 
(9.2% vs. 5.3%) and had a higher level of education; 50.1% vs. 43.3% had more than 12 
years of education. Even though the numbers were low, it was also more common in women 
with PsA to have pre-pregnancy hypertension (1.4%) or diabetes mellitus (1.3%) compared to 
non-PsA women (0.8% and 0.5%, respectively). 
In the main analysis of 921 PsA pregnancies vs. 9210 non-PsA pregnancies, we observed 
increased risk of preterm birth aOR of 1.69, 95%CI 1.27-2.24. There were also statistically 
significant increased risks for spontaneous onset and medically indicated preterm birth as 
well as for moderately preterm birth, but not for very preterm birth. Also, there was an 
elevated risk of caesarean delivery, both elective aOR 1.77, 95%CI 1.43-2.20 and emergency 
aOR 1.42 95%CI 1.10-1.84. There were no differences in risk of pre-eclampsia, gestational 
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diabetes or hypertension, SGA or LGA in PsA pregnancies compared to non-PsA 
pregnancies. 
Generally, throughout the stratified analyses based on different aspects of antirheumatic 
treatment, we observed increased risks of preterm birth and caesarean delivery in all analyses. 
Risk of pre-eclampsia was increased only in the analysis of PsA with bDMARD treatment 
during pregnancy compared to non-PsA pregnancies aOR 2.88, 95% CI 1.35-6.17. We did 
not observe an increased risk of gestational diabetes nor gestational hypertension in any 
analysis. Further, there was no indication in proportions or when assessing adjusted ORs 
(including adjustment for BMI, country of birth, parity and smoking apart from the matching 
factors) of increased risk of SGA birth. Regarding LGA the results differed, with an increased 
risk in PsA pregnancies with any treatment before and/or during pregnancy compared to non-
PsA pregnancies 6.6% vs. 3.9% and aOR 1.59, 95% CI 1.02-2.48. Among PsA pregnancies 
with treatment only before pregnancy 7.7% had a LGA birth vs. 3.9% in non-PsA 
pregnancies, aOR 1.76, 95% CI 0.95-3.24. Among PsA pregnancies with treatment during 
pregnancy 5.9% had a LGA birth aOR 1.48, 95% CI 0.82-2.68 compared to non-PsA 
pregnancies. There were 7.8% LGA births among bDMARD treated pregnancies aOR 2.21, 
95% CI 0.97-5.05 compared with non-PsA pregnancies. 
5.3.3 Analyses of preterm birth stratified on presence, timing and type of 
antirheumatic treatment 
Compared with non-PsA pregnancies where 4.6% had a preterm birth, there were higher 
proportions of preterm birth in all stratified subgroups of PsA. Stratified on presence of 
treatment, no vs. any treatment; 7.1% of PsA pregnancies without treatment one year before 
or during pregnancy (n=495) delivered preterm as compared to 8.9% of the PsA pregnancies 
with any treatment during the time frame. When exposure was stratified on timing of 
treatment, 7.7% of pregnancies with treatment only before pregnancy (n=170) delivered 
preterm compared to 9.8% of those with treatment during pregnancy (n=256). And finally 
when pregnancies with treatment during pregnancy were further stratified into type of 
treatment, non-bDMARD and bDMARD treatment, 4.6% of the pregnancies with non-
bDMARDs treatment had a preterm birth in contrast to 17.5% of those with bDMARDs. 
In Table 11, the different aspects of preterm birth – overall estimate, stratified regarding onset 
and stratified by gestational age – are presented with stratified exposure with respect to 
presence of treatment. In Table 12 this is presented with respect to timing of treatment and, 




5.3.3.1 Preterm birth with respect to presence of antirheumatic treatment 
There was increased risk of medically indicated preterm birth among PsA pregnancies 
without any treatment one year before pregnancy until birth, aOR 2.23, 95%CI 1.29-3.86. 
However, no other significant increased risk of preterm birth was noted compared to non-PsA 
pregnancies. Among the PsA pregnancies with treatment any time before and/or during 
pregnancy, there were increased risks of preterm birth, spontaneous preterm birth and 
moderately preterm birth (Table 11). 
Table 11. Percentages and adjusted ORs of different components of preterm birth in 
analyses with exposure of PsA stratified on presence of antirheumatic treatment 
compared with non-PsA pregnancies. Preterm birth is defined as birth before 37+0 
gestational weeks (gw), moderately preterm birth=32+0-36+6 gw and very preterm 






















 n (%) n (%) aOR* (95% CI) n (%) aOR* (95% CI) 
Preterm birth  417 (4.6) 35 (7.1) 1.43 (0.96-2.12) 38 (8.9) 1.98 (1.37-2.86) 
Spontaneous 
onset 
277 (3.0) 18 (3.7) 0.98 (0.58-1.69) 25 (5.9) 1.98 (1.27-3.09) 
Medically 
indicated  
140 (1.5) 17 (3.5) 2.23 (1.29-3.86) 13 (3.1) 1.86 (0.98-3.50) 
Very preterm  61 (0.7) 5 (1.0) 1.82 (0.66-5.00) 2 (0.5) - 
Moderately 
preterm  
356 (3.9) 30 (6.2) 1.38 (0.90-2.11) 36 (8.5) 2.15 (1.47-3.14) 
*Adjustments were made for maternal age, country of birth, year of birth, parity, educational level, smoking 




5.3.3.2 Preterm birth with respect to timing of antirheumatic treatment 
Among PsA pregnancies with antirheumatic treatment only before pregnancy, there were no 
statistically significant increased risks of preterm birth. On the contrary, among PsA 
pregnancies with treatment during pregnancy there were increased risks of preterm birth, 
spontaneous preterm birth and moderately preterm birth (Table 12). 
Table 12. Percentages and adjusted ORs of different components of preterm birth in 
analyses with exposure of PsA stratified on timing of antirheumatic treatment compared 
with non-PsA pregnancies. Preterm birth is defined as birth before 37+0 gestational 




























Preterm birth 417 (4.6) 13 (7.7) 1.44 (0.75-2.77) 25 (9.8) 2.30 (1.49-3.56) 
Spontaneous 
preterm 
277 (3.0) 8 (4.7) 1.25 (0.55-2.86) 17 (6.6) 2.43 (1.45-4.06) 
Medically 
indicated 
140 (1.5) 5 (3.0) 1.76 (0.63-4.91) 8 (3.1) 1.90 (0.88-4.13) 
Very preterm 61 (0.7) 2 (1.2) - 0 (0.0) - 
Moderately 
preterm 
356 (3.9) 11 (6.6) 1.44 (0.72-2.86) 25 (9.8) 2.58 (1.66-4.00) 
*Adjustments were made for maternal age, country of birth, year of birth, parity, educational level, smoking 
status and BMI 
 
5.3.3.3 Preterm birth with respect to type of antirheumatic treatment during pregnancy 
PsA pregnancies with antirheumatic treatment during pregnancy were stratified on those 
treated with non-bDMARDs (corticosteroids and/or cDMARDs) and bDMARDs 
(exclusively or in combination with corticosteroids and/or cDMARDs). 153 pregnancies were 
identified with non-bDMARD treatment and 103 with bDMARD treatment. Among the 153 
pregnancies with non-bDMARD treatment there was no increased risk of preterm birth. On 
the contrary, among the 103 pregnancies with the bDMARD treatment the risks of preterm 
birth were increased. The aOR for spontaneous birth among PsA pregnancies with bDMARD 
treatment compared to non-PsA pregnancies was 4.49, 95% CI 2.60-7.79. For spontaneous 
onset preterm birth aOR 4.73, 95% CI 2.53-8.87, for medically indicated preterm birth the 
aOR was 3.29, 95% CI 1.28-8.46 and aOR for moderately preterm birth was increased as 
well, 5.06, 95% CI 2.91-8.79 (Table 13). 
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Table 13. Percentages and adjusted ORs of different components of preterm birth in 
analyses with exposure of PsA stratified on type of antirheumatic treatment compared 
with non-PsA pregnancies. Preterm birth is defined as birth before 37+0 gestational 


























Preterm birth 417 (4.6) 7 (4.6) 1.08 (0.50-2.33) 18 (17.5) 4.49 (2.60-7.79) 
Spontaneous 
onset 
277 (3.0) 5 (3.3) 1.15 (0.46-2.85) 12 (11.7) 4.73 (2.53-8.87) 
Medically 
indicated  
140 (1.5) 2 (1.3) - 6 (5.8) 3.29 (1.28-8.46) 
Very preterm 
birth 
61 (0.7) 0 (0.0) - 0 (0.0) - 
Moderately 
preterm 
356 (3.9) 7 (4.6) 1.21 (0.56-2.62) 18 (17.5) 5.06 (2.91-8.79) 
*Adjustments were made for maternal age, country of birth, year of birth, parity, educational level, 
smoking status and BMI 
5.3.4 Description of types of antirheumatic treatment during pregnancy 
A more detailed description of type of antirheumatic treatment during pregnancy is presented 
in Figure 3. In summary, among the 153 pregnancies with non-bDMARD treatment, the 
majority, 128 pregnancies, had treatment with monotherapy (64 exclusively cDMARD and 
64 exclusively corticosteroids) and 25 pregnancies had a combination of cDMARD and 
corticosteroids. Among the 103 pregnancies with bDMARD treatment, 46 pregnancies were 
treated with bDMARD as monotherapy, and 47 were treated with a combination of two 
types, either bDMARD and cDMARD (10) or a combination of bDMARD and 
corticosteroids (37). Ten pregnancies were identified with a combination of bDMARD, 
cDMARD and corticosteroids. 
5.3.5 Analysis of preterm birth stratified on parity 
Because there was an interaction between exposure status, i.e. PsA or non-PsA pregnancy, 
and parity when we analysed the outcome preterm birth, we stratified the analyses on parity 
in the different exposure groups based on presence and timing of antirheumatic treatment. 
Generally, we found increased risk of preterm birth in first PsA pregnancies compared to first 
non-PsA pregnancies. Among subsequent PsA births compared to non-PsA subsequent 
births, there was no difference regarding risk of preterm birth. 
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Figure 4. Proportions and adjusted ORs for preterm birth in matched (maternal age and year 
of birth) cohorts with respect to presence and timing of antirheumatic treatment comparing 
PsA pregnancies with non-PsA pregnancies stratified on parity. Adjustments were made for 
country of birth, smoking status, educational level and BMI. 
 
5.4 STUDY IV 
5.4.1 Summary of main findings study IV 
In this cohort study of 211 pregnancies with psoriatic arthritis, we found a numerical but not 
statistically significant difference in the proportion of pregnancies complicated by preterm 
birth in women with (vs. without) active PsA disease during the study period from one year 
before pregnancy until delivery. 
5.4.2 Main results in study IV 
Maternal characteristics, such as maternal age, smoking habits, educational level, BMI, 
calendar year of birth and parity did not differ between pregnancies with a registered 
moderate to high DAS28CRP value compared to pregnancies without. Neither was there a 
difference when the three subgroups of pregnancies were compared, i.e. pregnancies with a 
registered value of DAS28CRP during the study period (high-moderate or low) as well as 
pregnancies without a registration. 
Thus, there was a difference in pattern of antirheumatic treatment. 31.7% of pregnancies 
without DAS28CRP registration did not use any antirheumatic treatment during the study 
period, compared with pregnancies with a registered moderate-high activity where 15% did 
not use any treatment and pregnancies with low activity where 10.9% did not use treatment. 
Comparing proportions of pregnancies that did not use any treatment between moderate-high 
activity and low activity did not differ Table 14. Further there was a corresponding difference 
in use of bDMARDs (Table 14). 
PsA pregnancies (n=921)
First 181/3390 (5.4) 45/339 (13.3) 2.50 (1.72-3.62)
Subsequent 263/5820 (4.1) 26/582 (4.8) 1.09 (0.70-1.71)
First 99/1750 (5.7) 21/175 (12.1) 1.97 (1.15-3.38)
Subsequent 126/3200 (4.0) 14/320 (4.4) 1.06 (0.56-2.01)
First 82/1640 (5.0) 24/164 (14.6) 3.14 (1.85-5.32)
Subsequent 110/2620 (4.2) 14/262 (5.4) 1.15 (0.61-2.17)
PsA pregnancies with treatment only before pregnancy (n=170)
First 20/460 (4.4) 9/46(19.6) 3.95 (1.43-10.95)
Subsequent 54/1240 (4.4) 4/124(3.3) -
PsA pregnancies with treatment during pregnancy (n=256)
First 62/1180 (5.3) 15/118 (12.7) 2.92 (1.55-5.52)
Subsequent 56/1380 (4.1) 10/138 (7.3) 1.59 (0.73-3.45)
PsA pregnancies with treatment before and/or during pregnancy (n=426)
PsA pregnancies 
PsA pregnancies without treatment before and/or during pregnancy (n=495)
Non-PsA 
pregnancies
n preterm birth/N total  pregnancies (%)
Adjusted OR* (95 % CI)
0,0 1,0 2,0 3,0 4,0 5,0 6,0
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Table 14. Proportions of anti-rheumatic treatment any time during the study period, 







value ≥3.2 any 























 n (%) n (%) n (%)   
No antirheumatic 
treatment 
7 (15.2) 7 (10.9) 32 (31.7) 0.51 <0.05 
Corticosteroids 22 (47.8) 24 (37.5) 40 (39.6) 0.29 0.53 
cDMARD 23 (50.0) 28 (43.8) 35 (34.7) 0.52 0.18 
bDMARD 34 (73.9) 46 (71.9) 32 (31.7) 0.81 <0.05 
* P-values for differences between the two groups with available disease activity measures were performed with the use of Fisher’s exact 
test. 
** P-values for differences of categorical variables between the three groups were performed with the use of Chi square/Fisher’s exact test 
depending on cell size 
5.4.3 Disease activity and preterm birth 
Due to low number of registrations during pregnancy, we collapsed the time strata into two 
time periods: i) any time during the time frame of the study and ii) in the year before start of 
pregnancy. 
13% of the pregnancies with a registered moderate-high disease activity any time during the 
time frame of the study had a preterm birth compared to 7.8% among pregnancies with 
registered low disease activity and 7.9% among pregnancies without a registration. If HAQ 
was used as a measure of disease activity, 12.9% had preterm birth among pregnancies with a 
score ≥0.5 compared to 7.1% in pregnancies with low activity and 7.5% in those with no 
registration. 
If the time frame was shifted to include just the year before pregnancy, 14.6% of the 
pregnancies with registered moderate-high disease activity had a preterm birth compared to 
9.6% of pregnancies with a registered low disease activity and 6.8% of pregnancies without 
registration. When HAQ was used, 12.8% of pregnancies with a HAQ score >0.5 had a 
preterm birth compared to 10% of pregnancies with HAQ score ≤ 0.5 and 7.0% of 
pregnancies without registration. 




6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Study design 
To decide on appropriate study design is a balance between validity (the degree to which the 
information collected accurately answers the research question) and efficiency. A randomised 
control trial is the gold standard for analytic studies however, for many research questions a 
randomised control trial can be considered unethical or problematic (for example assignment 
of harmful exposures) why an observational design can be the best alternative. The cohort 
design is common in epidemiological studies and the Swedish population based registers 
provide a unique source of information for such studies. 
In a cohort study, participants or study subjects are defined based on exposure. A cohort 
study can be prospective (participants are included before or at the time of exposure) or 
retrospective (the study begins after the exposure). In a retrospective design the risk of bias 
can be minimised if the information on exposure is recorded in a prospective manner and is 
registered independently of the outcome, this is common in register based cohort studies such 
as the studies included in this thesis. Cohort studies are well suited to study associations of 
rare exposures on specific outcomes, as the exposures included in the studies included in this 
thesis. 
In study I, II and III we used the NPR, which has national coverage since 1987 for inpatient 
care and since 2001 for outpatient care, to identify exposure and with linkage to the MBR we 
had the opportunity to use pre-existing, prospectively collected information (i.e. information 
on BMI, smoking habits and country of birth) before the outcome (s) occurred. The MBR has 
almost full coverage of all births in Sweden since 1973. In study IV we identified exposure 
in SRQ and the outcomes in the MBR. A major limitation of register based cohort studies this 
is that information on exposure, outcome and potential confounders are restricted to 
information collected in the registers. A prospective cohort study with information collected 
for the purpose of the study would not have this limitation but would, taken the rare 
exposures in this thesis into account be, difficult to complete. 
6.1.2 Systematic error 
Systematic errors are non-random. They occur due to incorrect selection of study population, 
incorrect measurement of the studied variables or disregard for other factors that can 
influence the results (confounders). To increase sample size cannot affect systematic error. 
6.1.3 Validity 
The validity of a study consists of two components, i) internal validity which can be 
described as the extent to which the observed results represent the truth in the study 
population and ii) external validity which means generalisability of the findings to other 
populations. The major threats to internal validity are systematic errors (selection bias, 
information bias and confounding). If the internal validity is limited, the external validity will 
be affected as well. 
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6.1.4 Selection bias 
Selection bias can be introduced if the association of exposure and outcome differs between 
those that participate in a study vs. the source population i.e. from the population from which 
the study population is sampled or recruited, this can lead to an under- or overestimation of 
the true association. Since both the NPR and the MBR are population based it limits the issue 
of selection, at least after 2001 when the outpatient component of the NPR became 
nationwide. In study I where information of exposure was collected during a long time 
period and started before the outpatient component of the NPR was nationwide there is a risk 
of a selection of more seriously ill study subjects who needed in patient care which could 
affect the outcomes studied. However we performed sensitivity analyses to explore this and it 
did not seem to affect the result. In study I, II and III we excluded pregnancies with systemic 
inflammatory diseases (from the study cohort) which is a selection but it affects the 
generalisability of the study more than the internal validity. Further, in study I-IV we 
included only singleton pregnancies limiting the generalisability to just singleton pregnancies. 
In study I and III we performed complete case analysis were pregnancies without full 
information on all variables were excluded from the analysis, if the pregnancies with missing 
information on variables are different than those with complete information this could 
introduce selection bias. In study II and III the population comparator pregnancies were 
initially sampled based on age and year at the index person’s diagnosis and county of 
residence with the assumption that they were free from diagnosis of various chronic 
inflammatory arthritis diagnosis at the time the index person was diagnosed. They could 
theoretically develop a disease from that time point. We did not use the original matching in 
our studies but used all of the recruited population control subject with a registered birth in 
the MBR as a comparator cohort. These comparator pregnancies may be healthier than the 
source population and can thereby introduce a larger difference in the relation 
exposed/unexposed if this affects various pregnancy outcomes. Further, in study IV we used 
the SRQ for identification of subjects with PsA and for information of exposure, there may be 
a difference in registration of disease activity depending on disease duration and disease 
severity as well as type of treatment with less registration of pregnancies in remission for a 
long time or with a stable low activity but this is however a speculation. 
Generally, when using the MBR there is a selection of pregnancies that complete 22+0 
gestational weeks which is when inclusion in the MBR occurs. This may lead to undetected 
pregnancy complications that arises before this gestational length if there is an abortion 
before 22+0 gw. Complications arising early in pregnancy but with a birth >22+0 gw will 
however still be detected. 
6.1.5 Information bias 
Information bias occur when information about the exposure or the outcome of study subjects 
is systematically inaccurate, i.e. misclassified. Misclassification can be differential or non-
differential depending on whether measurement error of one variable correlates with the 
measurement of another variable. When the misclassification is different in the exposed and 
non-exposed groups it is differential and leads to under- or over-estimation of the true 
association. Non-differential misclassification occurs equally in the exposed and unexposed 
groups and will typically lead to a dilution of the association of the exposure and outcome. In 
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study I we used one registered diagnosis in NPR but with requirement of a listing in 
rheumatology, internal medicine or paediatric departments to increase validity and decrease 
risk of misclassification of exposure. However, when we performed a sensitivity analysis 
with use of two separate visits or listings the point estimates were lower than in the original 
analysis and did not remain statistically significant in the subgroup JIA confined to childhood 
but did not affect the results in the subgroup JIA persisting into adulthood. This may indicate 
that we captured other conditions, more unspecific with only one diagnosis. Possibly these 
conditions should be closely related to JIA but not systemic inflammatory conditions which 
were excluded from the study cohort. Thus, misclassification of exposure in the subgroup JIA 
confined to childhood cannot be ruled out. In study II and III we used the criteria of at least 
two visits or listings with ICD-codes and at least one assigned from the department of 
rheumatology or internal medicine to reduce risk of misclassification of exposure. To date 
there are no validation studies of the diagnosis of PsA in the NPR. In study IV the risk of 
misclassification of exposure are most likely small due to the fact that the diagnosis registered 
in SRQ are assigned by the treating rheumatologist. 
Many of the outcomes in all studies included in this thesis are data that are routinely collected 
during pregnancy and delivery and are not dependent on if the pregnancy is affected by JIA 
or PsA. However, a pregnancy in a woman with a chronic condition may be under more tight 
surveillance and thereby complications can be detected more often which can result in 
surveillance or detection bias. In Sweden, all women have free access to antenatal care and 
are offered regular visits during pregnancy. In study I where diagnosis of exposure is 
dependent on registrations before 18 years of age it may lead to an underreporting of 
childhood onset arthritis in women who immigrate to Sweden after 18 years of age and thus 
they will be misclassified as unexposed. 
In study III we used information on antirheumatic treatment as a proxy for disease severity. 
The information about anti rheumatic treatment is based on dispensed prescriptions and for 
infusion of infliximab, information from SRQ. In study III we defined stratified groups 
based on treatment pattern. There may be women who collect their drug from the pharmacy 
but do not use it which leads to misclassification of exposure, disease severity and 
conclusions based on the treatment exposure may be wrong. On the other hand there may be 
women who have collected drugs at the pharmacy just before the study period started or, as 
with corticosteroids do have a supply at home to use in case of a flare. This will be 
undetected if not a new dispensation at the pharmacy is needed. Those pregnancies are 
misclassified as non-treated even though they use antirheumatic treatment. Misclassification 
of antirheumatic treatment in study III can be bi-directional i.e. both under- and overestimate 
the disease severity. 
6.1.6 Confounding 
A confounder is a variable that is associated with both the exposure and the outcome but is 
not an intermediate in the causal pathway. The concept of confounding implies that the effect 
of the studied exposure is distorted by effects of other variables-confounders which leads to a 
misrepresentative result. Unidentified confounders in a study may affect and alter the true 
association between an exposure and outcome. Risk factors for adverse pregnancy outcomes 
can, if they are unevenly distributed among the unexposed and exposed groups act as a 
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confounder but a risk factor is not a confounder by default. Confounding can be considered in 
the study design by randomisation, matching, stratification or restriction. In a large study 
population randomisation can reduce or eliminate both known and unknown confounders. 
Restriction is when you select study subjects with similar characteristics for variables that 
might be confounders but restriction in itself can introduce selection bias and affect external 
validity. Matching on variables that are potential confounders ensures an equal distribution of 
the variables among exposed and unexposed. 
In the analysis of data both stratified analysis and adjustment in a multivariable regression 
model can be used to reduce confounding. 
Many of the variables describing maternal characteristics in all of the studies included in this 
thesis can act as confounders and the information is mainly collected from the MBR. In study 
I-III maternal age, year of birth, maternal country of birth, educational level, smoking habits 
and BMI and parity were considered to be confounders 
6.1.6.1 Maternal age 
In study I the maternal age was younger among the exposed pregnancies than in the 
population comparator pregnancies and in study II and III the exposed women (pregnancies) 
were older than non-PsA women. Maternal age over 30 is associated with increased risks of 
preterm birth, stillbirth, caesarean deliveries and gestational diabetes (96-102). There are also 
studies indicating that young maternal age is associated with increased risk of various adverse 
outcomes (102-105). Maternal age is also related to parity why this has to be considered. 
Since maternal age was differently distributed among exposed and unexposed we treated this 
variable as a confounder and adjusted for this variable in the regression analyses in study I-
III and matched on maternal age in the main analysis in study III. 
6.1.6.2 Calendar year of birth 
Calendar year can reflect changes in procedures in health care that is not dependent on the 
exposure or outcome under study as such but for example, the different versions of ICD-
codes that is used to define exposure may capture the diagnosis differently. Also, indications 
for outcome procedures such as induction of labour and caesarean deliveries may change 
with time. Criteria for diagnoses can change, i.e. for gestational diabetes the criteria for 
diagnosis was changed in Sweden 2015. The new criteria used a lower glucose value as a 
threshold for diagnosis than earlier. This leads to increased number of pregnancies with a 
diagnosis of gestational diabetes. Also, the criteria for diagnosis of pre-eclampsia was 
changed in Sweden during 2019. This may alter the prevalence over time. Changes of 
definitions affects the possibility to compare risk of these outcomes over time. Prescription 
and treatment patterns for antirheumatic drugs and available antirheumatic treatments have 
changed over the study periods of the studies included in this thesis. In study I where time 
from start of exposure to outcome is many years, the women with JIA may have been treated 
in childhood and adolescence with antirheumatic drugs that nowadays would be considered 
suboptimal due to new and better treatment options of today. This may lead to a more active 
disease during longer time periods and consequently increased risk of joint destruction and 
secondary effects of active inflammation, especially if diagnosed and treated before 
bDMARDS were available. In study I-III there were differences in how the births in the 
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exposed compared to non-exposed pregnancies were distributed over the years. Calendar 
time, measured as year of birth, is considered a confounder in study I-III. 
6.1.6.3 Maternal country of birth 
There is more than one aspect of how country of birth can act as a confounder affecting the 
association between exposure and outcome. For several inflammatory diseases a genetic 
predisposition and an environmental trigger are of importance for the risk of developing the 
diseases. The incidence of arthritis diseases varies in different parts of the world and most 
incidence studies have focused on RA, the most common chronic inflammatory arthritis 
disease. In the northern part of the world, incidence rates for RA are generally higher than in 
the southern part (106). In study I-III exposed women were more often born in the Nordic 
countries than unexposed. Further, immigrant women in Sweden have increased risk of 
preterm birth compared to Swedish born comparators (107). Immigrant women from sub-
Saharan Africa, Latin America and the Caribbean are also reported to have an increased risk 
of pre-eclampsia compared to native born women in different industrialised countries 
including Sweden (108). We adjusted for country of birth, categorised into Nordic and Non-
Nordic, in study I-III. 
6.1.6.4 Educational level 
Highest level of attained education, categorised into ≤12 years or >12 years of education, was 
used as a proxy of socio-economic status in the studies included in this thesis. There are some 
evidence that JIA may affect highest attained level of education (109), may risk to affect 
school attendance (110) and that a diagnosis of chronic inflammatory arthritis affects working 
life (111-113). Low educational level and low socio-economic status, measured in different 
ways, are associated with adverse pregnancy outcomes (114-118). In the Swedish National 
Board of Health and Welfare’s yearly report from December 2020, maternal age-standardised 
characteristics and selected delivery outcomes are presented by attained educational level 
(119). The report indicates a relationship between attained educational level and smoking as 
well as with overweight and obesity. A lower proportion, 0.8%, are smokers among women 
with more than 12 years of education as compared to 11.9% smokers among women with 9 
years of education. In women with the highest level of education the proportion of obesity 
was 11.4% and in the group with lowest education 25.7%. 
Adjustments for educational level were performed in study I-III. 
6.1.6.5 Smoking habits 
Smoking during pregnancy is associated with adverse pregnancy outcomes (foetal growth 
restriction, preterm birth, placental abruption and stillbirth) (120, 121). The proportion of 
women who report that they were smokers at first antenatal visit during pregnancy have 
dramatically decreased during the last 20 years (122). In 1992, the first year of the study 
period in study I, 22.9% were smokers at the first antenatal visit and in 2017, the last year of 
the study period in study III, 4.6% were reported as smokers (122). Smoking is a risk factor 
for RA (123) but have a more uncertain role in PsA, it seems that smokers in the general 
population have an increased risk to develop PsA compared to non-smokers but smokers 
among persons with psoriasis seem to have a decreased risk to develop PsA compared to non-
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smokers (124). However, in study I-III there were more smokers in the exposed group 
compared to the unexposed. We adjusted for smoking status in study I-III. 
6.1.6.6 BMI 
Both maternal underweight (BMI <18.5) and overweight (BMI 25.0-29.9) as well as obesity 
(BMI >30) have been reported to be associated with preterm birth (125, 126). Overweight 
and obesity is also associated with increased risk for post term birth (125). Obesity is 
associated with gestational diabetes (127), gestational hypertension and pre-eclampsia (128-
130), LGA birth (131, 132), stillbirth and infant death (133-135). In addition, obesity is 
associated with caesarean delivery (136-138). Among birthing women in Sweden obesity and 
overweight are associated with country of birth and socioeconomic factors where women 
with lower level of education have increased risk of obesity (139). 
In study I-III there were differences of BMI distributions between exposed and unexposed 
groups. We adjusted for BMI in study I-III but also modelled effect of exposure on 
outcomes without BMI adjustment in study II. 
6.1.6.7 Parity 
Parity is a description of the number of pregnancies that have passed beyond the gestational 
age of viability at birth, live or stillbirth. 
Generally, women with inflammatory diseases are reported to have reduced fertility but the 
reason for this is most likely multifactorial and includes factors as disease activity, use of 
antirheumatic drugs and psychological factors (140-143). In a population based Norwegian 
study of births 1967-1995, published in 2001 the authors report increased maternal mean age 
at first birth, and lower mean age in subsequent births indicating a shorter reproductive 
period. This finding was however altered by time period of the study, with increased 
subsequent pregnancy rate with time (144). 
For all women, irrespectively of rheumatic disease, there are data indicating that adverse 
pregnancy outcomes can affect decisions about future pregnancies. For example, in a 
population cohort study of singleton pregnancies in Norway with births 1967-1996 the 
association of mode of delivery and the probability to have a future birth was dependent on 
infant survival the first year after birth. If the infant was stillborn or died there was no 
association between mode of delivery and chance of a future birth. If there was a live born 
infant there was a lower rate of women that had a future birth after caesarean delivery in all 
maternal age groups, among low-risk pregnancies and in subgroups with pre-eclampsia and 
breech presentation (145). 
In the general birthing population, there is a described recurrence risk of for pre-eclampsia 
(146, 147), SGA birth (148-150) and preterm birth (151-153), conditions that are to some 
extent interrelated. A pregnancy and delivery after a first caesarean birth is associated with 
more complications compared to a first vaginal birth (154-157). 
A population based study from Norway showed that adverse pregnancy outcomes such as 
pre-eclampsia, SGA birth and preterm birth had a higher recurrence rate in women with 
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rheumatic diseases (including connective tissue diseases, RA, JIA AS and non-specified 
inflammatory arthritis diseases) as compared to women without rheumatic diseases (158). 
Further there are studies that report increased adverse pregnancy outcomes associated with 
first birth after diagnosis of inflammatory joint disease (4) but not subsequent, and greater 
differences in first births than subsequent (15). 
In study I we adjusted for parity in the analyses, in study II and III we both adjusted and 
stratified for parity in the analyses and in study III we matched when we assembled the study 
cohort. 
6.1.6.8 Residual confounding 
Residual confounding is confounding that remains after controlling for confounding in the 
design or /and analyses in a study. There are several reasons for residual confounding where 
one is the existence of confounding factors that were not considered either due to lack of data 
for these factors or that no attempt was done to adjust for them. Other reasons for residual 
confounding are that the control is not enough to reduce the total effect of the confounder or 
measurement errors in the confounding variables. Unmeasured maternal factors and residual 
confounding might be present in all studies included in this thesis. 
6.1.6.9 Confounding by indication 
Confounding by indication or channelling bias arises when subjects who receives an 
intervention or drug are inherently different from those who do. In study IV in which the 
exposure was a registered value of disease activity is the exposure we kept pregnancies 
without the registered measure for comparison in the study since we hypothesised that 
increased disease activity, a more severe disease or treatment with bDMARD might affect the 
possibility of having a registration in SRQ and at the same time these factors are associated to 
the outcome under study. 
6.1.7 External validity 
In study I the study cohort comprises all births in the MBR during the study period and are 
population based and nationwide as well as the NPR which was used for identification of 
exposure. However only singleton pregnancies were included in study I as well as in study 
II-IV which influences the generalisability to multiple births. In study II, the included 
pregnancies were diagnosed with PsA before their first birth which also may influence 
generalisability of these results to subsequent births after diagnosis. The results from all the 
studies in this thesis may not be generalizable to other populations with different accessibility 
of maternity care. 
6.1.8 Random error 
Random error refers to variability in data that is due to chance. It can be reduced by increased 
sample size and thereby increase precision. Statistical techniques such as p-values and 
confidence intervals can be used to quantify the degree of precision in the observed estimates. 
In this thesis the confidence levels were set to 95% in study I-III. Several of the pregnancy 
and delivery outcomes of interest are rare i.e. pre-eclampsia and preterm birth and so even if 
the underlying cohort size was large the precision was somewhat hampered in study II and 
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III. In study IV we may have seen a difference in risk of preterm birth when we compared 
pregnancies with moderate-high active PsA with low active PsA if the size of the study 
cohort had been larger. 
6.2 FINDINGS AND IMPLICATIONS 
The main exposures studied in the work included this thesis, JIA and PsA, are each captured 
by only a few ICD codes, although the diagnosis and underlying diseases themselves are 
multifaceted and defined more by the relationship of the condition as contrasted to other 
conditions than by a specific set of symptoms. As such, they are “entities” rather than distinct 
diagnoses with symptoms and presentation changing with a patient’s age and over time. For 
these reasons, it became apparent that studying these exposures involved a great deal of 
complexity. Nevertheless, given the sparsity of studies addressing these conditions’ effects on 
pregnancy available when the work with this thesis started, I think it is important to address 
these conditions. 
6.2.1 Inflammation and time 
In study I, we studied the effects of a history of a diagnosis of arthritis before 18 years of age 
in relation to pregnancy outcomes. We found two distinct patterns of inpatient and outpatient 
visits. We defined two groups based on these patterns: JIA pediatric only and JIA persisting 
into adulthood. In each of these groups, there may be a different distribution of JIA 
subgroups, but we were not able to study this. JIA is not one disease, and the subgroups each 
have different features and underlying pathology (40). Thus, a Swedish longitudinal study of 
JIA patients concluded that there was a “considerable and continuous change in JIA 
categories during the study period”, (159) why this may be of less importance. 
We found differences in the two subgroups. JIA paediatric only consisted of the majority of 
JIA pregnancies. Even though we considered these pregnancies to lack actual or recent 
inflammatory activity, we found increased odds of preterm delivery, moderately preterm 
delivery and medically indicated delivery. Further, induction of labour was more common 
among JIA paediatric pregnancies vs. population pregnancies, and the aORs for caesarean 
delivery, both emergency and elective, were increased. In an analysis of proportions of pre-
eclampsia by adverse outcomes, there was no explanation of the adverse outcomes from 
diagnosis of pre-eclampsia in the JIA paediatric group. This may be due to residual effects of 
past inflammation, which may affect endothelial function and the structure of vessels; (160-
162), this however remains a speculation. Diagnosis of JIA persisting into adulthood was 
associated with an increased risk of pre-eclampsia, preterm birth and SGA birth. All of these 
outcomes may be related. Unfortunately, the indications of induction of labour and caesarean 
delivery are not entered into the MBR in such a way as to provide a variable for study. This is 
an aspect of register studies that needs to be considered. However, even though we do not 
know about antirheumatic treatment or disease activity during pregnancy, we can clearly 
demonstrate that a diagnosis of JIA with ongoing course into adulthood is associated with 
increased risk of adverse pregnancy outcomes. The presence of pre-eclampsia seems to be the 
major driver for other adverse outcomes, judging by the proportions of pre-eclampsia among 
JIA in comparison with population pregnancies in selected adverse outcomes. Of the preterm 
births in JIA persisting into adulthood, 22.9% also had a diagnosis of pre-eclampsia, 
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compared to 12.4% in population comparator births. Among the medically indicated preterm 
births in JIA persisting, 45.5% had a diagnosis of pre-eclampsia compared to 36.6% in 
population comparator births. In SGA births, 32.1% in JIA had a diagnosis of pre-eclampsia 
vs. 14.3% in population comparator births. The differences in caesarean deliveries were not 
striking. 
Pre-eclampsia has earlier been characterised by abnormal placentation and endothelial 
dysfunction, with early onset pre-eclampsia being characterised by defect placentation and 
late onset pre-eclampsia more affected by maternal metabolic factors such as diabetes (163). 
New evidence suggests that the maternal cardiovascular system in itself plays a role in the 
pathogenesis of pre-eclampsia (164). Individuals with rheumatic diseases have an increased 
risk of CVD, thought to be caused in part by elevated levels of factors such as circulating pro-
inflammatory cytokines, circulating autoantibodies and specific T cell subsets. Taken 
together, this is believed to drive the increased CVD risk by promoting the formation of 
atherosclerotic plaques and cardiovascular remodelling (165). 
Given the results of this study with increased risk of early onset and late onset pre-eclampsia, 
SGA birth, and spontaneous as well as medically indicated preterm birth and of very as well 
as moderately preterm birth in JIA persisting into adulthood, I suggest that we consider low 
dose aspirin to this group of women as prophylaxis for pre-eclampsia. 
6.2.2 Psoriatic arthritis and pregnancy outcomes 
In studies II, III and IV, the exposure variable includes diagnosis of PsA. 
In study II, we found that diagnosis of PsA was interrelated with obesity and smoking, as 
well as with other rheumatic co-morbidities and with IBD. The previously published studies 
about PsA and pregnancy outcomes at the time of conduction of our study were small. For 
example, they did not include any information on BMI. One of the studies published, a 
Danish-Swedish population based cohort study of Pso and PsA, reported similar maternal 
characteristics as ours among the 964 studied PsA pregnancies. Their study cohort consisted 
of approximately 2/3 subsequent births. 13% were smokers, 17% had a BMI >30 and 14% 
had diagnosis of RA. In conclusion, their study cohort was similar to ours, except regarding 
parity. In our cohort, approximately 50% of the exposed pregnancies were overweight or 
obese, 60% were first pregnancies, and 5.9% had a diagnosis of RA. We considered our 
cohort to be representative of PsA pregnancies in the Nordic countries at least. 
When we modeled our regression model, we abstained from adjusting for BMI in one of the 
analyses and included BMI as a confounder in the fully adjusted model. This was because of 
an uncertainty about how to handle obesity in relation to PsA, i.e. whether it should be 
considered as “a part of the entity” or if the arthritis disease in itself could cause obesity via 
for example physical inactivity. Obesity is described as an important co-morbidity in PsA, 
and is also a risk factor for developing psoriasis in the general population. Data further 
support that the prevalence of obesity increases when the severity of psoriasis increases (94). 
The association of PsA with obesity may be described as bi-directional, as illustrated by 
studies indicating that weight gain can be a consequence of decreased physical activity in 
persons with joint dysfunction. Obesity is concomitant with an ongoing low grade of 
inflammation. Studies indicate an increase in many cytokines as well as interleukin (IL)-17 
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and IL-23 plasma levels in obese women compared with lean individuals. A higher risk of 
developing obesity in PsA patients may be due to common pathophysiological mechanisms 
(166, 167). 
In the analyses comparing outcomes in PsA vs. non-PsA pregnancies, the effect of also 
including BMI as a confounder was generally minor, why we interpreted our results as an 
effect of PsA and not of obesity alone. 
In the main analysis of outcomes in PsA pregnancies compared to non-PsA pregnancies, we 
noted increased aORs of preterm birth, spontaneous preterm birth, medically indicated 
preterm birth and moderately preterm birth. There was also an increased risk of caesarean 
delivery, both by the overall estimate and when stratified as elective. When we stratified the 
analysis by parity, the risk of preterm birth was further attenuated among first pregnancies but 
was not present in subsequent births. The increased risk of caesarean delivery was intact 
among subsequent births, and now also significant for the strata of emergency caesareans. An 
interesting finding among the subsequent births was an increased point estimate of pre-
eclampsia, however this was not statistically significant. aOR for pre-eclampsia in the main 
analysis of PsA vs. non-PsA was 1.21, 95% CI 0.78-1.88 in the fully adjusted model. Among 
subsequent pregnancies, aOR in the fully adjusted model was 1.77, 95% CI 0.77-4.11. The 
proportion of pregnancies with pre-eclampsia was very low, namely 2.8% among PsA 
pregnancies vs. 1.5% in non-PsA pregnancies. 
After an analysis in a restricted cohort with exclusion of pregnancies with co-morbidities 
before pregnancy, the estimates of preterm birth overall and caesarean delivery remained 
increased. 
We interpreted the main result of a higher risk of preterm birth as originating from exposure 
to PsA. In this study of PsA, study II, there was no risk of pre-eclampsia nor SGA. The large 
difference in outcomes compared to our study of JIA is challenging. In study II, we did not 
have information on disease activity or antirheumatic treatment. This was also true for the 
JIA study, study I, but there, we had an indication that patients had lived for a presumably 
long time with a chronic inflammatory disease. In the study by Bröms, pregnancies with PsA 
had an increased risk of gestational hypertension and pre-eclampsia but not of SGA birth 
(72). 
In study III, we wanted to assess disease severity by the proxy of antirheumatic treatment, 
under the hypothesis that an antirheumatic treatment with more than one drug or treatment 
with bDMARD during pregnancy is an indicator of a more severe disease than a pregnancy 
without antirheumatic treatment. We further hypothesised that there may be decisions and 
changes in antirheumatic treatment in the year preceding a pregnancy that we do not capture 
if we were to assess only antirheumatic treatment pattern during pregnancy. 
In the Swedish guidelines from SRF regarding anti-inflammatory and immune modulating 
treatment during pregnancy and breastfeeding, the general advice is to plan a pregnancy to a 
period with low disease activity or remission. The current advice regarding TNFi is to stop 
treatment if disease is in remission or at a low activity. For women with moderate to high 
disease activity, treatment with selected TNFi:s can continue, but an evaluation before 
gestational week 30 is suggested. This advice is due to the increased transport of antibodies 
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(IgG1) over placenta, predominantly during the third trimester. If there is a strong indication, 
the treatment can continue. The best studied bDMARDs during pregnancy are certolizumab 
pegol and adalimumab and they are approved by the European Medicines Agency, EMA, for 
use during pregnancy. Treatment with certolizumab pegol (no Fc part) and etanercept 
(soluble TNF-receptor) results in less transport of the drug over the placenta, compared to 
substances with complete IgG1 (infliximab, adalimumab and golimumab) (168). In study III, 
we collapsed TNFi and other biologic treatments into “bDMARD” for simplicity, and 
categorised treatment further in cDMARD for conventional DMARDs and CS for 
corticosteroids. 
In study III, we studied the exposure of PsA stratified on presence, timing and type of anti-
rheumatic treatment. However, in the main analysis, before stratification there were increased 
risks of preterm births and caesarean deliveries but not of pre-eclampsia, SGA or LGA birth. 
Interestingly, among pregnancies without any dispensed antirheumatic treatment one year 
before pregnancy until delivery, there were increased risks of medically indicated preterm 
birth and elective caesarean delivery compared to non-PsA pregnancies. The stratified 
analyses differed by timing of treatment with the most increased risks in pregnancies with 
treatment during pregnancy, especially bDMARD treatment. We noted the most increased 
risks in PsA pregnancies with bDMARD treatment during pregnancy. Among those 
pregnancies, there was an increased risk of pre-eclampsia, aOR 2.88, 95% CI 1.35-6.16, as 
well as increased risks of preterm birth, spontaneous preterm birth and moderately preterm 
birth as compared to non-PsA pregnancies. We interpret this as meaning that those 
pregnancies have an indication to continue, or start, with antirheumatic treatment during 
pregnancy based on a presumably more severe disease than a pregnancy without treatment. 
However, from clinical experience, we know that women may abstain from treatment even 
though they have an indication, due to a fear of complications from the drug itself. 
In a systematic review and meta-analysis of bDMARD treatment before and during 
pregnancy in women with chronic inflammatory arthritis and IBD, (169) there was no 
association between use of bDMARD during pregnancy and risk of preterm birth compared 
to non-bDMARD exposed disease comparators. A population based study of pregnant 
women with various inflammatory diseases (IBD, RA, AS, PsA, and Pso) reported adverse 
pregnancy outcomes in women treated with TNFi compared to women with non-biologic 
systemic treatment (170). The authors concluded that the diverse findings across disease 
groups may indicate an association related to the underlying disease activity, rather than 
agent-specific effects. 
Preterm birth is a complex outcome which is important to recognise, because it is a leading 
cause of morbidity and mortality in the neonate (171-173). When studying preterm birth, it is 
important to investigate or assess different reasons for the onset of preterm birth, because 
they may reflect different underlying causes. There are studies indicating a genetic pre 
disposition for preterm birth (174, 175) and hereditary factors are described to be involved in 
approximately 25% of the cases (173). Cytokines, such as interleukin-1 (IL1), IL6, IL8, and 
TNFα, plays a role in preterm birth, (174, 176) as well as in chronic arthritis diseases (78, 
177). A genetic overlap has been suggested between IBD and preterm birth (174) but there 
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are no such publications, to my knowledge, for genetic overlap in chronic inflammatory 
arthritis diseases and preterm birth. 
Spontaneous preterm birth, defined as spontaneous onset labour with contractions or 
premature pre-labour rupture of membranes and birth before 37 gw, most likely has a multi-
factorial underlying cause (171, 178, 179). Several factors have been linked to increased risk 
of spontaneous preterm birth: previous preterm birth (180), maternal overweight and obesity 
(126), underweight (181), diabetes (182, 183), and smoking (184), among others. An 
association between spontaneous preterm birth and RA and other autoimmune diseases has 
been reported earlier (10, 185). 
In study III, we found that the risk of spontaneous preterm birth ranged from being 
comparable to that for non-PsA pregnancies among pregnancies without any antirheumatic 
treatment to showing a fourfold increased risk in pregnancies with bDMARD treatment 
during pregnancy. These findings strengthened our hypothesis that disease severity has an 
impact on risk, at least with regard to spontaneous onset preterm birth. 
In contrast, medically indicated preterm birth reflects pregnancy complications, but is also 
influenced by obstetric management. As such, stratifying by parity can be a way of assessing 
this. An interesting publication addresses the mediation of adverse outcomes, for example 
preterm birth and cesarean delivery, in autoimmune diseases. The strongest mediator for 
preterm birth in pregnancies with RA, SLE and psoriasis was pre-eclampsia/hypertensive 
disease, accounting for 20-33% of excess risk (186). This may be what we noted in study I, 
even though we did not perform a mediation analysis. 
There is sparse knowledge of the effect of disease activity on preterm birth in PsA 
pregnancies (77). Disease activity flares and increased disease activity during pregnancy have 
been associated with preterm birth in studies of other rheumatic diseases such as SLE (187), 
RA (27, 39, 188) axial spondyloarthritis (188), and JIA, (39) so this scenario seems plausible. 
We therefore conducted study IV, in which diagnosis of PsA was defined according to the 
treating rheumatologist entering data into the SRQ. In the cohort of PsA pregnancies, we used 
values of DAS28CRP and HAQ as exposure, defining a DAS28CRP <3.2 as low disease 
activity and a value of DAS28CRP ≥3.2 as moderate to high. A HAQ score of >0.5 was here 
considered as active PsA disease. We used the time frame from one year before pregnancy 
until birth as the study period for each pregnancy, the time period was divided into seven 
strata. The study was unfortunately hampered by the availability of few registered values 
during pregnancy and hence, the proportions are imprecise. In any event, this is an important 
finding as such. We used the best possible data from a decade of pregnancies, and the data 
were still sparse. This is not exclusive to this study. Ursin et al. (76) included 108 PsA 
pregnancies in a study of disease activity during and after pregnancy 2006-2017. Only 38 
(35%) of the pregnancies had a pre conception visit and 32 of the 38 (84%) of these 
pregnancies had a registered value of DAS28CRP. The time frame for the pre conception 
visit in the study was any time one year before pregnancy. However, during the study period 
there were increased rates of both visits and registered values of DAS28CRP.  
A study of pregnancy outcomes in DMARD treated women with JIA from Germany included 
152 pregnancies with JIA 2007-2018. It was based on data from a JIA biologic register in 
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combination with a follow up register- both these German registers are described as 
multicenter prospective observational cohort studies. Patients were assessed every 6 months 
of a rheumatologist and patient reported outcomes were routinely evaluated every 6 months. 
Physician and patient reports within 12 months before, during and up to 6 months after 
pregnancy were included in the analyses. Patients were also asked to participate in a 
structured interview early in pregnancy and 6 months after delivery. The authors describe that 
on average there was 1.6 physician and 3.0 patient reports available from the study period (12 
months before pregnancy, during and until 6 months after delivery). In the analyses, missing 
values for clinical Juvenile Arthritis DAS-10 were imputed. 
To conclude: our studies indicate that in general a PsA pregnancy is associated with increased 
risk of preterm delivery and caesarean delivery compared to non-PsA pregnancies. These 
associations do not seem to be due the unfavorable maternal characteristics that are more 
frequent in PsA pregnancies and also risk factors for preterm birth. 
Parity influences risk of preterm birth in PsA pregnancies compared to non-PsA pregnancies 
and the association is mainly confined to first pregnancies. The reason for this however 
remains unclear. 
Further, when antirheumatic treatment is used as a proxy for disease severity PsA 
pregnancies considered to have the most severe disease with ongoing bDMARD treatment 
during pregnancy also exhibits the most severe adverse outcomes compared to non PsA 
pregnancies. 
Disease activity in PsA pregnancies may be associated to preterm birth, we noted numerical 
differences in proportion of preterm in moderate-high active vs. low active PsA. The study 
was hampered by sparse data and low precision. This question needs to be further evaluated 
in a prospective manner in the future. 
The findings in studies II and III implies that first pregnancies, especially in women with 





i) Pregnancies in women with JIA have increased risks for adverse outcomes 
including pre-eclampsia, SGA birth, preterm birth and ceaserean delivery. 
ii) Pregnancies in women with PsA have increased risks for preterm birth and 
caesarean delivery. 
iii) Even though women with PsA have more co-morbidities, are more obese and 
more often smoke than women without such a diagnosis, the adverse pregnancy 
outcomes are not due solely because of these factors. 
iv) Parity influences risk of preterm birth in PsA pregnancies and the increased risk is 
predominantly seen in first births. 
v) When antirheumatic treatment is used as a proxy for PsA disease severity, the 
most increased adverse outcomes, compared to pregnancies without PsA, are seen 




8 POINTS OF PERSPECTIVE 
Based on the findings in study I-IV the following questions are raised 
i) What instrument should be used to measure disease activity during pregnancy? 
ii) When is it valuable to assess disease activity during pregnancy? 
iii) How do we assess, in a prospective and detailed way, what antirheumatic 
treatment that is actually used? 
iv) What are the indications of caesarean deliveries and induction of labour? 
v) Can we by increased surveillance during pregnancy improve outcomes? 
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